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One of the most common clinical decisions a Sports and Exercise Medicine (SEM) physician is 
required to make is whether an athlete presenting with symptoms or signs of an acute illness can 
participate in exercise training or competition. Currently, a clinical tool, known as the ‘neck 
check’ is used to determine eligibility to participate in exercise training or competition athletes 
with acute illness. This original clinical tool, first described about 20 years ago, was based mainly 
on an abbreviated medical history and findings of a clinical examination were excluded. 
Symptoms of illness ‘above-the-neck’ e.g. sneezing, rhinorrhoea or sinus congestion constitute a 
‘passed’ “neck check”, whereas ‘below-the-neck’ symptoms e.g. cough and/or systemic 
symptoms such as fever and myalgia, constitute a ‘failed’ “neck check”. However, in the current 
literature, there remain very few data regarding 1) the adherence of athletes to advice given 
following a ‘neck check’, and 2) whether the exercise performance (e.g. the ability to finish a 
race) or the development of medical complications during exercise is different in athletes who 
“passed” or “failed” the ‘neck check’.   
 
Objective  
The main objectives of this dissertation are: 1) to review the available evidence with respect to 
medical assessment and participation risk in endurance runners presenting with symptoms of 
acute illness before a road race; 2) to document the range of acute illnesses in runners presenting 
in the 3 days before a race; 3) to determine adherence to advice given by medical staff to these 
runners, and 4) to determine the effects of the outcomes of the medical assessment on running 
performance particularly, the ability to finish the race and the medical complications experienced 
during the race.  These data are important to improve the medical care of runners (and other 
athletes) presenting with acute illness before training and competition. 
 
Methods  
Phase 1: Review of the literature 
All literature relating to the epidemiology of acute illness in athletes, risk factors for illness, and 
participation risk, potential medical complications and effects on performance of exercising 
whilst ill were sourced using established electronic databases (PubMed, Medline, Google 
Scholar). In addition, literature related to the background of the ‘neck check’, as well as the 
evolution of the current RTP guidelines in athletes with acute illness were sourced.   
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Phase 2: Research study 
In a prospective cohort study, 242 runners who presented to a pre-race registration medical 
facility with medical concerns were assessed by SEM physicians by means of medical history and 
physical examination (if indicated) using a specific Pre-Race acute Illness Medical Assessment 
(PRIMA group). 172 of these runners had evidence suggesting acute infective illness (PRIMA-I 
group) and 70 runners had non-infective complaints (PRIMA-N/I group). The epidemiology 
(prevalence rate = % runners) of runners with symptoms, signs and specific clinical diagnoses of 
acute illnesses were documented in the PRIMA-I group. Following clinical evaluation, all the 
runners in the PRIMA-I group were then advised regarding clearance to run the race, monitoring 
symptoms, or not running the race, using the ‘neck check’ as a guideline. Runners in the PRIMA 
cohort were then tracked during and immediately after the race, and the following parameters 
were compared to those in a control group of runners not presenting to the medical facility at 
registration (CON=53 734): 1) incidence of not starting of the race (per 1000 runners) (DNS 
rate), 2) incidence of not finishing the race in those who started (per 1000 runners) (DNF rate), 




Phase 1: Review 
The main finding of the review is the relative paucity in clinical data with respect to participation 
in athletes with acute illness. Upper respiratory tract symptoms are very common in athletes, and 
the risk factors are discussed. Furthermore, there are different aetiologies underlying athletes’ 
URT symptoms (other than infection). The documented risks of exercising when systemically ill 
include sudden cardiac death and reduced pulmonary function, splenic rupture in patients with 
infectious mononucleosis, and dehydration and electrolyte disturbances when exercising with 
acute gastro-intestinal illness. There is little evidence in the literature regarding the effects of 
illness on performance; these include reduced performance, non-participation and the potential 
effects of WARI (wheezing after respiratory tract infection). Evidence supporting the two aspects 
of the neck check is reviewed: the presumed safety of exercising with localised URT symptoms, 
and the perceived risk of exercising with lower respiratory tract or systemic symptoms. Clinical 
data are severely lacking, and the available data are based on self-reported symptomatology. 




Phase 2:  
In the PRIMA-I cohort of 172 runners, the most common symptoms were sinus congestion 
(40.1%), cough (38.2%), sore throat (37.8%) and runny nose (25.6%). More than half the cohort 
(57.5%) had a diagnosis of localised URTI. However, URTI with generalised symptoms was the 
single most common diagnosis (22.7%). In the PRIMA-I group, 41.3% of the runners failed the 
‘neck check’. Compared with the CON group, there was no significant difference in the DNS rate 
in the PRIMA-I group. However, in those runners who were advised not to run, the DNS rate was 
565 per 1000 runners, and this was significantly higher than that of the CON group (192 per 1000 
runners) (p<0.0001). PRIMA-I race starters had a higher DNF rate (31 per 1000 runners), and 
runners with any medical concerns (PRIMA group) had a significantly higher DNF rate (37 per 
1000 runners) compared to the CON group of runners who started the race (15 per 1000 runners) 
(p= 0.0329). There were no documented medical complications in the PRIMA-I group who 
started the race, while the MC rate of the CON group was 6.7 per 1000 runners. In runners in the 
PRIMA-I group who had been advised not to run, 43.5% were non-adherent, and started the race 
despite this advice.    
 
Conclusion  
Our study indicates that localised upper respiratory tract infection is responsible for the majority 
of acute illness in a pre-race cohort of runners. Furthermore, the data provide some evidence that 
it is safe for runners with acute illness to exercise if they pass the ‘neck check’. However, 
presenting to a pre-race registration medical facility, failing the ‘neck check’ and receiving advice 
against participation appear to increase the risk of not finishing a race. There is also concern 
about the high rate of non-adherence to advice given by the SEM physician. Finally, a pre-race 
registration medical assessment for runners with acute illness may reduce the risk of developing 
short-term medical complications during the race. 
 




Introduction and scope of the thesis 
 
One of the most challenging clinical decisions a Sport and Exercise Medicine (SEM) physician is 
required to make is: “When can an athlete with symptoms of a recent or current acute illness train 
or compete?” In this context, most acute illnesses refer to infective illness, and this will be the 
focus of this dissertation. Where appropriate, other non-infective acute illness will be specifically 
highlighted.   
 
This apparently simple question conceals a myriad of complex clinical, health and safety, 
performance, and even medico-legal issues, all of which the SEM physician needs to consider. 
Some of the pertinent questions are: 
 Are athletes at particular higher risk for becoming acutely ill (with infective illness), and if 
so, why?   
 When, if ever, is it safe to exercise whilst sick, or does it depend on the type of acute 
infective illness?   
 What are the theoretical and documented risks of exercising whilst acutely ill with an 
infection? When is it safe to return to play after acute infective illness?   
 What are the guidelines for the athlete, and do they adhere to the advice given by the SEM 
physician? 
 
Modern day evidence-based medicine (EBM) requires SEM physicians to keep abreast of the 
latest evidence and guidelines regarding management strategies, as for all other specialities.  
Therefore, a fundamental question for the SEM physician is whether there are any EBM 
guidelines to address the above-mentioned questions.   
 
In this dissertation, the first aim will be to review the existing literature, and to explore the current 
evidence to answer the above-mentioned questions (Chapter 2). More specifically, in Chapter 2 
the available literature regarding acute illness and exercise, with a focus on what is relevant to 
participation guidelines, will be reviewed. The first section in this Chapter will explore the 
assessment of the acutely ill athlete from multiple perspectives, including the epidemiology and 
risk factors of symptoms of infection. 
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The second half of Chapter 2 aims to explore available return-to-play (RTP) guidelines following 
acute infections. Safe RTP advice requires a solid evidence base on which to build safe RTP 
guidelines. It is this evidence base which will be under scrutiny. 
 
In Chapter 3, the details of an original research study will be presented. The aim of this 
prospective cohort study in 172 runners was to determine if runners who presented to a pre-race 
registration medical facility with acute illness, and then clinically evaluated and advised 
regarding exercise participation: 1) adhered to advice (starting the race or not); 2) finished the 
race (in those who did start the race); and 3) required treatment at the race medical facilities 
(medical complications) (in those who started the race). These data will make a significant 
contribution towards the evidence base in this field of Sports and Exercise Medicine. To our 
knowledge, this is the first study that examines the application of the principles of the ‘neck 
check’ as the basis for RTP decisions, particularly evaluating athletes who exercise with 
symptoms of localised illness. Furthermore, it is also the first time that the concept of athletes’ 
adherence to RTP advice has been explored.  
 
Finally, in Chapter 4, the results from this dissertation will be summarised. Clinical guidelines for 













A review of participation guidelines for athletes 
presenting with symptoms of acute illness 
 
2.1.   Introduction 
 
Traditionally, the role of the Sport and Exercise Medicine (SEM) physician has been pivotal in 
the assessment, diagnosis and management of sports injuries, together with the management of 
chronic medical conditions in athletes, both recreational and elite. Over the past two decades the 
literature indicates an increasing interest in diagnosis and management of acute illness in athletes.   
 
Infections are common in athletes, and SEM physicians are required to accurately identify 
symptoms of infection and manage athletes appropriately. For the athlete, the most important 
question is usually: “When can I exercise again?” There are many factors that may influence the 
physician’s decision: some are medical, but others include external factors such as pressure from 
family, coaches and other players. Creighton et al described a 3-step decision-based model for 
return-to-play (RTP) after illness or injury, although their model mostly discusses injury (1).   
 
The first step is the ‘Health Assessment’ of the athlete, considering the relevant medical factors, 
including history, examination and special investigations. The second step is ‘Participation risk’, 
considering athlete-specific factors e.g. their type of sport, and in the context of illness, the 
required aerobic capacity. This step requires knowledge of the potential complications of 
exercising with the acute illness. The third and final step considers ‘Decision modifiers’, which 
introduce external factors such as the type and level of competition and pressure from coaches 
etc. These modifiers may alter the participation risk for an athlete’s health status at a given time.  
It should be noted that the acceptable risk threshold for each individual might differ (1). 
Creighton’s model will provide the basic structure for the first part of this literature review.   
 
‘Health assessment’ is the first step in the decision-making process when faced with an athlete 
who has symptoms of acute illness, and will thus be the first area to be reviewed. The SEM 
physician should be cognizant of the multi-faceted nature of the assessment. The epidemiology of 
acute illness in athletes in the pre-competition period will also be briefly discussed, as well as the 
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risk factors for developing acute illness during this time. It has been proposed that some acute 
upper respiratory tract symptoms, presumed to be infectious in origin, may in fact have a different 
aetiology, and the evidence for this will be reviewed.   
 
The second part of the ‘Health Assessment’ will focus on the medical factors that comprise the 
clinical evaluation of the athlete. Most of the evidence in the literature consists of 
epidemiological studies where athletes have self-reported symptoms of infection during periods 
of training or after competition. An accurate health assessment requires a sound clinical diagnosis 
based on a medical history and a physical examination. In this section of the review the role of 
clinical evaluation in athletes with symptoms of illness will be explored. An accurate diagnosis, 
especially depending on whether the aetiology is infective or other, is key to effective 
management and consequently, safe RTP advice.  
 
The second step in Creighton’s model is ‘Participation Risk’. Although Creighton’s discussion is 
focused on injury, the concept is equally pertinent in illness. This section of the review will 
therefore discuss the evidence regarding potential medical complications of exercising whilst 
suffering from an acute illness, as well as the potential effects on exercise performance. 
Understanding the participation risks when ill is an essential element of providing safe RTP 
advice. However, there is a paucity of literature on this topic, and data are mostly from 
epidemiological studies, or from a limited number of animal studies. Part of the reason for the 
paucity in data is that it would be unethical to perform randomized studies in acutely ill athletes.   
 
The potential risks of exercising when ill are often difficult to quantify, and each athlete may 
have an individual threshold of “acceptable risk’. Furthermore, this threshold may change 
depending on the third step of Creighton’s model – ‘Decision modifiers’. This last step will only 
be mentioned briefly in the review. Decisions therefore need to be discussed with the athlete, and 
other role players such as the coach to ensure that informed decisions are made. However, it is 
most important that the SEM physician takes the final RTP decision (2, 3). 
 
The second part of the literature review will explore the evidence base for current RTP guidelines 
in athletes with acute illness. RTP guidelines need to consider all of the issues discussed in the 
first half of this chapter. Ideally, these guidelines should be evidence-based, as required of other 
guidelines in the medical field e.g. the rigorous data, both clinical and economic, required for the 
NICE (National Institute for Health and Care Excellence) guidelines in the UK. The evidence that 
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is required for the development of a RTP guideline should be specific for the illness, and may be 
modified by the athlete’s sport. Besides the issues that will be discussed under Creighton’s model, 
other considerations include:  
 Is there a difference in risk between localised vs. systemic infection? 
 Is there a difference in risk, which is related to the primary site of the infection?   
 Is the risk associated with the specific infective organism, or the symptoms?   
 If there is evidence of harm, is it due to the infective organism, or associated systemic 
symptoms if they are present?   
 Is there a risk of transmission of the illness to other athletes? 
 
It should also be noted that both the SEM physician, as well as the athlete, need to be in 
agreement about their definition of RTP e.g. anywhere on the spectrum from partial training at 
low exercise intensity to full competition without any restriction. Once a guideline has been 
developed, it is ideal to have evidence of clinical impact, and this will be discussed with the 
Bethesda guidelines for RTP after myocarditis. 
 
Current RTP guidelines for athletes following acute illness are based on a clinical tool known as 
the ‘neck check’. Therefore, the evidence base for this guideline and the evolution thereof will be 
discussed.  For the remainder of this dissertation, this clinical tool and guideline will be referred 
to as the neck check. Currently, evidence-based RTP guidelines only exist for two defined 
infective conditions: myocarditis and infectious mononucleosis (IM) (3-8).   
 
2.2.   ‘Health Assessment’ of the athlete with symptoms of  
acute illness 
 
In this section the epidemiology of upper respiratory tract symptoms (URTS) in athletes, as well 
as the risk factors for symptoms of upper respiratory tract infection (URTI) will first be reviewed.  
Thereafter, the role of the ‘health assessment’, specifically the clinical evaluation in an athlete 






2.2.1.  Epidemiology of acute illness in athletes in the pre-competition     
 period 
 
2.2.1.1.  Introduction 
 
In the past 2-3 decades, the majority of the literature relating symptoms of acute infective illness 
to exercise participation has been from the field of exercise immunology. This field has largely 
focused on the measurements of immunological responses to acute exercise bouts or regular 
exercise training, mostly in healthy participants. In very few studies, have any acutely ill athletes 
been studied, or have clinical measurements and outcomes been determined. Although there have 
been some excellent reviews of the known changes in the immune system following an acute bout 
of strenuous exercise (9, 10), there are very limited applications of these data to the clinician 
faced with RTP guidelines for an acutely ill athlete. Therefore, it is outside the scope of this 
Chapter to perform a detailed review of the immunological response to acute and chronic exercise 
by the immune system. However, some of the relevant aspects will be briefly reviewed. It is very 
important to note that, to date, no causative relationship has been established between exercise-
related immunological changes and the apparent increased risk of URTI in athletes, or the 
increase in post-race URTS (9, 11). 
 
Furthermore, there are almost no data regarding the epidemiology of acute illness in athletes in 
the pre-competition period. As previously mentioned, most of the clinical data in exercise 
immunology have been based on self-reported symptomatology by athletes. More recently, data 
have been reported regarding illness patterns in different groups of athletes from different 
sporting codes and ability levels (elite vs. recreational).   
 
For a long time, it was presumed that the upper respiratory tract symptoms seen in athletes post-
competition were infectious in nature (hence URT Infection - URTI). However, a growing body 
of evidence suggests that upper respiratory tract (URT) symptoms are also common in the pre-
competition period and may have a non-infective aetiology; thus they should rather be referred to 
as URT symptoms (URTS) (12-18).   
 
These non-infective URT symptoms may also be responsible for many of the symptoms which 
appear to comprise the athlete’s general ‘increased risk of infection’ (12, 17), thereby correlating 
 17 
with pre-race URTS. There appears to be a strong link between pre- and post- race symptoms, 
suggesting a common aetiology and some of these data can be summarized as follows: 
 A study of 70 elite level athletes seen in a SEM clinic, reported a clinical diagnosis of viral / 
bacterial URTI in 87%. Infectious pathogens were only isolated in 57% (12).   
 A study of 104 ultra-distance marathon runners investigated post-race URTS. 35 runners 
developed URTS after the race, but there was no significant difference in pre- and post-race 
blood results (CRP, CBC, Serum IgA or ASOT). Viral and bacterial cultures failed to isolate 
anything other than scanty numbers of normal commensals (13).    
 Immunoglobulin levels were measured in 14 randomly selected Comrades (ultra-marathon) 
runners from 4 weeks before until 2 weeks after the race. The incidence of URTI was highest 
4 weeks prior and 7-14 days after the race. URTI symptoms were not associated with a 
change in secretory immunoglobulin levels, and there appeared to be a strong correlation 
between pre-race and post-race symptoms, suggesting re-activation of the underlying 
aetiology (19).   
 A strong correlation was shown between pre- and post-race self-reported symptoms in 1694 
Stockholm marathon runners (15).   
 A study investigating the prevalence of allergy in runners of the London Marathon showed 
that 40% of the runners were ’allergic’ before the race, as defined by a positive AQUA 
questionnaire and confirmatory raised total / specific IgE. Many allergic symptoms e.g. 
rhinitis, would be classified as URTS in a symptom questionnaire (17).   
 A prospective study of 32 elite triathletes, 31 recreational triathletes and 20 sedentary 
controls was carried out over a 5-month period, which spanned competition and training. An 
increase in URTS was found in the elite and control athletes, but a pathogen (mainly 
rhinovirus) was only isolated in less than 30% of these runners. Microscopy, culture, PCR 
and serology tests were all performed (16).   
 The use of topical “fusafungine” spray has been shown to reduce the incidence of post-race 
URTS by 23% in ultra-marathon runners. Viral and bacterial cultures were negative, 
suggesting that the aetiology was inflammatory rather than infective (18). 
 
These data are suggestive that not all URTS in athletes are infectious in origin, and that the SEM 
physician should consider other causes of URT inflammation, including allergies, as the cause of 
URT symptoms. If these symptoms (of as yet unknown aetiology) are present during general 
training and pre-race periods, it is quite feasible that the same aetiology is associated with the 
post-race symptoms.   
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2.2.1.2.  Epidemiology of URTI in the pre-competition period   
 
There are very few clinical data regarding the prevalence of acute illness in the pre-competition 
period. As discussed earlier, most of the data relate to self-reported symptoms only, and mostly 
on post-race URTS. Recent studies have reported the incidence of illness in tournament settings, 
where it has consistently been shown that respiratory symptoms are the most common, followed 
by gastro-enterological and dermatological symptoms respectively (20-25). A study of the 
incidence rate of acute illness in Paralympic athletes showed no difference between the 3 days 
pre-competition as compared to during the Games period (20). For many of these athletes, the 
timing of their illness would have corresponded with their pre-competition periods. Neither this 
study, nor those mentioned above, differentiated whether the athletes’ illness was pre- or post-
event.  
 
2.2.2.  Risk factors for acute illness in the pre-competition period  
 
The identification of risk factors of acute illness in athletes allows the SEM physician to address 
known modifiable risk factors so that preventative programs can be planned and implemented. In 
cases where non-infective aetiology may be implicated, the ability to recognise these factors may 
help direct appropriate management. Risk factors that may be associated with increased risk of 
illness (mainly URTS) will now be reviewed.   
 
2.2.2.1.  Increased training load causing increased URTS 
 
Over 20 years ago, it was suggested that the risk of developing URTS is related to the training 
load of the athlete (26). This relationship was described as a ‘J curve’ and was based on an 
analysis of a mixed cross-sectional cohort of marathon runners and sedentary people, as well as 
longitudinal studies in athletes and sedentary men and women (27).  According to this hypothesis, 
moderate exercise activity reduces the risk of developing URTS compared to sedentary people, 
whilst strenuous and/or prolonged exercise increases the risk of URTS (more so than for 
sedentary people) (Fig. 2.2.2.1.)(26). Evidence in support of this hypothesis was a documented 
increased incidence of URTS in elite triathletes compared with control subjects (16). Similar 
observations were reported in other studies to support this hypothesis (27).   
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However, an S-curve has also been described to define the relationship between training load and 
the development of URTS. This was described following a re-evaluation of published data, and 
adapting the J curve to distinguish between ‘high load’ and ‘elite’ athletes, where the elite athletes 
were shown to have a lower risk for infection (Fig. 2.2.2.2 ) (27).  These relationships between 
training load and risk of URTS will have a direct impact on the risk of pre-competition illness, 
which is the focus of this dissertation. 
 
 
Fig. 2.2.2.1: The relationship between training load and risk of URTS (‘J shaped” curve) (26)  
 
 
Fig. 2.2.2.2: The relationship between training load and risk of URTS (‘S shaped” curve) (27)  
 
A review in 1993 examined the relationship between training load and URTS risk (28). However, 
the studies discussed in this review mainly focused on increased training mileage and the 
physiological stress of racing with respect to post-race URTS (29, 30). It has been shown that 
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training volumes of >97 km/week were associated with increased URTS during training periods, 
which would coincide with pre-race risk (30).  
 
However, not all studies are in accordance with these findings – a large study compared the point 
prevalence of self-reported illness 3 weeks before and after the Stockholm marathon. In this 
study, the pre-race prevalence of self-reported illness was 17% and the post-race incidence was 
19%. However, in those athletes without pre-race illness, the incidence of post-race illness was 
only 16%, thereby not supporting the hypothesis that URTS are increased after exhaustive 
exercise. Therefore the results of this study did not support the correlation between pre-race 
training volume (load) and increased post-race symptoms, but it did support the hypothesis that 
pre-race symptoms increase the risk of post-race symptoms (15).  
 
2.2.2.2.  Gender 
 
Several studies have reported a significantly higher incidence of illness in female athletes 
participating in tournament settings (23, 24, 31). In one study, the incidence of illness was more 
than double in female athletes participating in the Youth Olympic Games (22). However, in 
another study during the 2012 Paralympic Games there was no association between gender and 
overall risk of illness (20). 
 
2.2.2.3.  Age 
 
In some studies it has been documented that older age is associated with an increased risk of 
illness in athletes participating in tournaments. Older women were noted to have increased illness 
in the Winter Olympics (24) and older age was associated with increased illness in the IAAF 
tournament (31). However, this was not confirmed during the 2012 Paralympic Games where 




Recently, it has been shown that the incidence of acute illness in elite athletes increases by 2-3 
fold when travelling across more than 5-hour time zones to a distant country (32). This increased 
incidence returned to baseline on the athletes’ return to their home country.  This implied that the 
underlying reasons were factors related to the distant destination, as opposed to travel per se. 
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Travel allows for teammates to be in closer proximity for longer periods of time, increasing the 
risk of transmission of viral infection (33). Travel in general may also expose athletes to food-
borne illness, causing acute gastro-intestinal infection (34). These factors may certainly influence 




A pre-race screen of 208 runners at the 2010 London Marathon reported that 40% of runners had 
allergies, as defined by a positive AQUA questionnaire and a raised total or specific IgE. Runners 
with a history of infection in the 2 weeks pre-race were excluded from this study. The post-race 
incidence of URTS was 47%, and a history of allergy was a significant risk factor for URTS. The 
controls in this study were non-runners from the same household, and only 19% had symptoms, 
suggesting that many of the symptoms were not infectious in origin (17). Therefore, symptoms of 
allergy may mimic those of infection in the pre-competition period. 
 
2.2.2.6.  Environment 
 
It has been documented that a significant increase in respiratory symptoms is seen in winter 
endurance sports such as Nordic skiing and skating (24, 35). Bronchial hyper-reactivity has been 
noted in many of these winter endurance athletes, and it is postulated that a combination of 
factors may be responsible for this including: cooling and drying effect of breathing cold air, 
hyperpnoea-related epithelial injury, and inhalation of noxious gases in the case of indoor skating 
(35, 36). Training in such an environment would increase the risk of pre-competition respiratory 
tract symptoms in these sports. A clinical assessment would be particularly important to 
differentiate between inflammatory symptoms, and those presumed to be infectious in origin. 
 
2.2.2.7.  Type of sport 
 
In recent years, a number of studies reported differences in the incidence of illness in different 
sporting codes. More specifically, it has been shown that there was a higher incidence rate (IR) of 
illness in track and field athletes, compared with other sporting codes, during the 2012 
Paralympic Games (20). Similarly, data from swimmers participating in the FINA World 
championship showed that there was a significant difference in illness rates between the different 
aquatic disciplines (23).  
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2.2.2.8.  Other factors 
 
Individual susceptibility to infection may be influenced by an athlete’s immuno-competence, their 
response to exercise stress and recovery, exercise capacity and non-training stressors (10). Other 
factors that increase an individual’s vulnerability to infection have been described, but these have 
not been well investigated in athletes. These factors include 1) nutritional deficiencies (incl. 
micronutrients), 2) sleep disruption (reduced quantity and quality, as well as chronic sleep 
deprivation) and 3) chronic psychological stress (10).   
 
2.2.2.9.  Summary: Factors related to increased risk of illness 
 
In summary, risk factors that may increase the risk of symptoms of illness in the pre-competition 
period include: increased training volume, travel (especially across >5 time zones to a foreign 
destination), allergy, exercise environment, and type of sport. Female gender and increased age 
may also be risk factors, but this requires further investigation. 
 
2.2.3.  The role of a pre-race medical assessment in the athlete with    
   symptoms of acute illness in the pre-competition period 
 
A medical assessment, consisting of at least a medical history and a physical examination is the 
first step for any SEM physician when evaluating an athlete who presents with symptoms of an 
acute illness before a competition or a training session. Following this assessment, a sound 
clinical diagnosis can be made or further investigations may be performed. This can then be 
followed by advice on RTP. Anecdotally, there is evidence that RTP advice is often frequently 
given on the basis of symptoms only (medical history). However, as indicated in the previous 
section, upper respiratory tract symptoms may have different aetiologies, and therefore a physical 
examination is not only important to distinguish a non-infective from an infective cause of URTS, 
but also to distinguish localised from systemic symptomatology. These factors may influence the 
decision to compete, and also the risk of reduced exercise performance or medical complications. 
However, to our knowledge, this has not been studied in the context of RTP guidelines for acute 
illness in athletes.   
 
This section will review aspects of the clinical evaluation that would facilitate the assessment of 
the athlete with symptoms of acute illness. The medical history will be discussed first, with the 
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focus on the importance of clinical interpretation of constellations of symptoms. The following 
section will describe typical examination findings that suggest infection. Finally, the use of 
special investigations will be addressed, where these may be valuable in 1) differentiating 
infective from non-infective causes, and 2) obtaining a definitive diagnosis in the assessment of 
the athlete with symptoms of an acute illness before a competition.   
 
2.2.3.1.  Medical history 
 
The value of a clinician interpreting an athlete’s symptoms is significant. Many athletes presume 
their symptoms are infective in origin, but this may not always be the case (as previously 
discussed). The SEM physician is in a position to identify other aetiologies such as allergies. 
Common URTS such as rhinorrhoea (runny nose), sore eyes and pharyngeal discomfort may all 
be present in either an URTI, or be allergy-related. For a clear definition of an URTI, some 
authors have used a validated symptom checklist and recommended that an URTI required ≥3 
symptoms from this checklist (37). It has been established that allergies may be more prevalent in 
endurance athletes (17). Furthermore, URTS are more common in winter endurance athletes (35), 
where URT symptoms may also be related to high volumes of cold dry air causing mucosal 
injury, rather than infection.   
 
2.2.3.2.  Physical examination findings 
 
As far as we are aware, there are no published data on the specific value of findings on clinical 
examination in the RTP guidelines given to athletes presenting with an acute illness in the pre-
competition period. Current RTP guidelines after acute illness (the neck check) are based on self-
reported symptoms only. By inference, there is no mention in the literature of the indications for 
physical examination in athletes with symptoms of acute illness in the pre-competition period.   
When examining an athlete with symptoms of acute illness, one of the aims of the medical 
assessment is to differentiate infective from non-infective symptoms. However, it has been shown 
that clinicians may not always consider non-infective symptoms as a differential diagnosis for 
URTS (12). In this study, clinicians diagnosed 30% of athletes as having an infection for which 
there was no laboratory evidence.  
 
In order to diagnose a systemic inflammatory response syndrome (SIRS), two of the following 
four criteria are required for diagnosis (38): 
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1. Raised body temperature  
There are normative values for different sites of temperature measurement. Circadian rhythm 
should be borne in mind. With a move away from mercury glass thermometers, infra-red 
aural thermometers are now commonly used. A systematic review of the accuracy of 
peripheral aural (and oral) thermometry indicates that these methods give an accurate 
representation of core temperatures within the febrile range and can thus be recommended for 
this purpose (39).   
2. Raised resting heart rate (>90 beats / min)   
It is well established that a fever is associated with a tachycardia, as compensation for 
reduced stroke volume (SV) (8). Additionally, a difference of 10-20 beats / min in resting HR 
on waking in the morning may indicate the onset of illness or represent inadequate recovery 
(40, 41). This requires close monitoring of the athlete on a daily basis, and without this prior 
knowledge of the athlete’s normal values, it is limited as a criterion for decision-making in 
the clinical setting. In addition, athletes have a training-induced reduction in resting heart 
rate, and to use resting heart rate cut-offs from the general population is not appropriate.   
3. Increased respiratory rate (>20 breaths/min) 
It is well established that there might be tachypnoea in an acute systemic infective condition. 
This may be as a result of hyperventilation related to temperature regulation or hypoxia. 
4. Full blood count (FBC) - mainly white cell count (WCC)  
An abnormal WCC (>12 x109/L or <4 x 109/L, or >10% immature forms) is the fourth criteria 
that can be used to diagnose a SIRS.  
 
In most instances, team physicians and SEM physicians advising athletes with acute illness may 
not have the FBC results available in time to make the RTP decision. Therefore, as objective 
signs of a systemic illness, SEM physicians often have to rely on clinical signs (raised body 
temperature, increased resting heart rate and resting respiratory rate) to diagnose a SIRS. 
 
Furthermore, to determine the source of the infection, it is often difficult to differentiate between 
bacterial and viral causes of certain URT conditions such as sinusitis and pharyngitis. Both the 
medical history and a physical examination have a poor sensitivity and specificity for 
distinguishing between viral and bacterial causes (33). However, the Berg prediction rule has 
been used to help identify bacterial infection. According to this rule, the presence of focal sinus 
tenderness and purulent nasal discharge increase the risk of the causative organism being 
bacterial in nature (42). Allergy may produce sinus congestion as well, but in this case the nasal 
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discharge should be clear and no systemic symptoms (such as fever, myalgia or arthralgia) should 
be present. Lower respiratory tract symptoms such as a cough may be present as a result of a post 
nasal drip or concurrent asthma. Other symptoms such as sneezing and particularly itchy eyes 
may indicate the presence of allergy. Sinus aspiration culture is the gold standard for diagnosis of 
bacterial sinusitis, but is rarely used in a clinical setting.  
 
A sore throat may be a symptom of many clinical conditions including simple viral URTI, 
bacterial pharyngitis, or infectious mononucleosis (IM). It may also be associated with a post-
nasal drip or mouth breathing at night. Examination is thus indicated to identify the possibility of 
bacterial pharyngitis (usually due to Group A β-Haemolytic Streptococcal infection – GABHS), 
which is often difficult to distinguish from IM. Posterior cervical lymphadenopathy and 
additional signs such as splenomegaly or hepatosplenomegaly may be indicative of IM (42).  
 
As mentioned earlier, there is evidence that that laboratory-based classification provided better 
differentiation of infection than clinical diagnosis based on symptoms and signs. Predictors for 
partially distinguishing infective episodes included: presence of a high number of systemic 
symptoms, elevated WCC and neutrophilia, self-imposed training modifications and lower 
Vitamin D concentrations (12).   
 
2.2.3.3.  Special investigations 
 
The following discussion looks at three of the questions SEM physicians should be asking 
themselves when they see an athlete with symptom of acute illness, as the answers will obviously 
impact on their management, and consequently the RTP advice given: 
a) Is this illness a result of an infective process? If so, can a viral infection be differentiated 
from a bacterial infection? 
b) Is there evidence of specific conditions such as pharyngitis, where different aetiologies 
will have different RTP guidelines e.g. GABHS and IM? 
c) Can myocarditis be excluded? 
 
a) Is this an infective illness? Bacterial vs. viral? 
Traditionally, inflammatory markers such as ESR and CRP have been done, together with a WCC 
+ differential count. However, ESR, CRP and lactate have poor sensitivity and specificity for 
infection (38, 43). These are elevated in systemic inflammation, whatever the cause, be it auto-
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immune, surgical stress, burn stress or infection. A neutrophilia is the common response to 
bacterial infection, while a neutropaenia may be seen in viral infections.    
  
Novel biomarkers target bacterial sepsis, due to its high morbidity and mortality. Pro-calcitonin 
(PCT) is a strong indicator of bacterial infection (43). Although several new biomarkers have 
been identified for sepsis, none has ideal individual sensitivities or specificities. Examples of such 
biomarkers include Il-6 (Interleukin-6), LBP (lipopolysaccharide-binding protein), CD64 counts 
and TREM-1 (triggering receptor expressed on myeloid cell 1) (43-45). None of these are 
appropriate / practical for the classical SEM consultation, where a simple biomarker of infection 
would be helpful.   
 
Vitamin D: Reduced serum levels of Vitamin D have been associated with increasing incidence 
of URTI, but it is not yet clear how this association works. Levels have also been observed to 
deteriorate following infection, but this could not be explained by inflammatory changes only. It 
has been hypothesised that increased tissue requirements may be one of the factors responsible. 
Further studies are required to elucidate the role of Vitamin D in the immune system (46). 
 
In summary, there is no simple biomarker as yet to differentiate between inflammation and 
infection, and PCT may help to differentiate bacterial from viral infection. Further research is 
required. 
 
b)  Special investigations that may assist with differentiating the aetiology of  
pharyngitis include: 
 GABHS: Rapid assays and throat swabs are available to assist in confirmation / exclusion 
of the diagnosis; sensitivities approach 90% in both investigations, with a possibility of 
false negatives (47). The total WCC will be raised with a neutrophilic predominance (42). 
 IM:  A moderately raised WCC (12 000 – 18 000), with 60-70% lymphocytes and 10% 
atypical lymphocytes on peripheral smear are the common findings in a patient with IM.  
A relative neutropaenia and thrombocytopaenia are often observed. A monospot test (for 
heterophile antibodies) is specific for IM, but has a poor sensitivity of 75% in the first 
week of infection, which improves to 95% by the third week. The monospot test has poor 
sensitivity in children <10 yrs of age. EBV titres for viral capsid antigen may be checked 
for IgM (indicating acute infection) and IgG (indicating past infection) (42, 47). 
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c) A diagnosis of myocarditis needs to be excluded 
This is not a simple differential diagnosis as a number of complicating factors need to be taken 
into account and include: 
1. Time of year: a high index of suspicion is required, especially in the spring and summer 
months when enteroviruses are more prevalent – they often present with both respiratory 
and gastro-intestinal tract symptoms (48). 
2. Symptoms on medical history: these range from mimicking an acute MI (chest pain or 
dyspnoea), dysrhythmias (palpitations), acute congestive failure, syncope, fatigue to no 
cardiac symptoms at all (49). 
3. Physical examination findings: these may include muffled heart sounds, a tachycardia 
disproportionate to other findings, fever, mitral regurgitation and a pericardial friction rub 
if pericarditis is present (42). Signs of URTI may be the only presentation as myocarditis 
may be sub-acute. 
4. Resting ECG changes:  these may include:  
 Myocarditis: ventricular / supra-ventricular dysrhythmias, ST changes (usually 
depression), T wave inversion and occasionally left bundle branch block (LBBB) 
/ atrio-ventricular (AV) block (5).  
 Pericarditis: ST elevation may be seen with up-sloping ST segments (in these 
leads, no T wave inversion) (6).  
Note that ECG changes associated with the ‘athletic heart’ should not be misdiagnosed as 
myocarditis. These include hyperadrenergic T wave changes (which normalize with beta 
blockade), and early repolarisation changes (49).  
5.  Blood tests: routine markers of inflammation may be normal in myocarditis (4), 
therefore further investigations are required: Troponin T/I, and Myoglobin-binding 
fraction of CK (CK-MB) serum are suggested. Traditionally a CRP and a WCC + 
differential count are done as well.  ESR has been considered non-contributory (7).  
6. Echocardiography: transient global left ventricular dysfunction with reduced myocardial 






2.3. The risk of potential medical complications when 
exercising at the time of suffering from an acute illness: a 
review  
 
In this section, the potential medical complications of exercising at the time of suffering from an 
acute illness will be reviewed. The risk of medical potential complications during exercise is the 
cornerstone around which safe participation guidelines should be developed. Furthermore, 
evidence that exercise aggravates the illness should also be considered. It is also acknowledged 
that the risk of medical complications may depend on a number of factors, including the effects of 
systemic illness compared with a localised illness, the timing of exercise with respect to 
inoculation, and the effects of specific organism. Of particular concern is the risk of sudden 
cardiac death (SCD) during exercise as a result of infective myocarditis or myo-pericarditis, and 
the potential medical complications when suffering from infectious mononucleosis (IM) and 
acute gastro-intestinal illness. Finally, the risk of transmission of organisms during exercise is 
also a factor to be considered in mass sports participation events such as a distance running race.   
 
2.3.1. Potential medical complications of localised compared with  
systemic illness 
 
Current clinical guidelines regarding exercise participation when an athlete suffers from an acute 
illness are largely based on the hypothesis that a systemic illness is more likely to result in a 
medical complication compared with a localised illness. However, there is very little data to 
support this hypothesis. In a single study, it has been documented that exercise has no effect on 
symptom severity scores in subjects who were iatrogenically infected with rhinovirus. It is 
established that rhinovirus infection is localised and does not usually cause a viraemia (50). In 
this study, 34 moderately fit individuals were randomised to 10 days of 40 minutes of daily 
exercise at 70% HRR, after inoculation with rhinovirus, and compared with 16 control subjects of 
similar fitness, who did not exercise. Symptom severity scores (by questionnaire) were assessed 
every 12 hours, and facial tissue weights were used to measure symptom severity. This is one of 
the only clinical studies which supports the hypothesis that exercise with localised URTI 
symptoms is safer compared to exercising with systemic infective illness. To our knowledge, 
there are no other studies where the risk of medical complications during exercise is shown to be 
less when athletes suffer from localised compared with systemic illness. This requires urgent 
study, as the current clinical guidelines are based on this hypothesis. 
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2.3.2.  Potential medical complications related to the timing of 
inoculation 
 
The timing of exercise related to onset of illness has been investigated in a small number of 
animal studies. It has been reported that influenza infection increased the risk of death during 
exercise during the acute phase of an infection (8). There are also data to suggest that exercise 
during the incubation period of a systemic illness may worsen the severity of the illness (51), and 
that exercising in the acute phase of illness increases the risk of myocarditis (52). However, we 
are not aware of any published studies tracking the course of the illness, or the risk of medical 
complications in athletes with symptoms of acute infection.   
 
2.3.3. Risk of sudden cardiac death (SCD) during exercise as a 
complication of myo-pericarditis 
 
It has been documented that myo-pericarditis is one of the causes of sudden cardiac death during 
exercise, particularly in younger athletes (53). Although sudden cardiac death (SCD) is a rare 
complication of myocarditis, the risk of myocarditis in athletes with acute illness will be briefly 
reviewed.  
 
2.3.3.1.  Aetiology of myo-pericarditis 
 
Myocarditis and pericarditis are characterised by inflammation of the cardiac muscle and 
pericardium respectively, and often co-exist, thus leading to the term myo-pericarditis. It is 
usually infective in origin (49). In the past, coxsackie viruses A and B (part of the enterovirus 
family) were the most commonly implicated viruses in the aetiology of myo-pericarditis (≈ 50% 
of cases) (49). It has been suggested that selenium deficiency may increase the susceptibility of 
some populations to myocarditis from these viruses (49). Recently there has been evidence from 
endomyocardial biopsies that Parvovirus B19 and Human Herpes virus 6 are responsible for more 
cases of myo-pericarditis than previously thought (54). Other viruses that have been implicated 
include adenovirus, influenza virus, echovirus, HIV, EBV, CMV and hepatitis C (4-8). 
Rhinovirus, the most common cause of URTIs, has not been implicated (52). Bacterial causes of 
myo-pericarditis include *Streptococcus, Staphylococcus, Pneumococcus, Haemophilus and 
Neisseria (4).   
* This has implications for the management of the athlete with a streptococcal pharyngitis.   
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Atypical bacterial infections have also been reported as a cause for myo-pericarditis. Mycoplasma 
pneumonia was reported as the responsible organism in 6 % of military recruits with myocarditis 
(49), and other bacteria include Chlamydia pneumoniae, Borrelia burgdorferi (Lyme Disease) 
and Trypanosoma cruzi (Chagas’ Disease) (49, 52).  
 
2.3.3.2. Epidemiology of myo-pericarditis 
 
There are no epidemiological data on the incidence of myo-pericarditis in athletes presenting with 
acute illness. In the general population, there are also little data on the actual incidence of 
myocarditis, as many cases are subclinical. It appears that myo-pericarditis is more prevalent in 
males, particularly in the 20-40 year age group (42). Pericarditis is most frequently seen in young 
adults and is the cause of chest pain in 5% of admissions to the emergency department (6). 
Myocarditis may be the only presentation of an infection or it may be a complication of an 
apparently localised infection elsewhere e.g. URTI, and sub-clinical in nature (i.e. no cardiac 
symptoms) (49), with positive findings in up to 1% of autopsy cases (6).  
 
2.3.3.3. Known complications of myo-pericarditis 
 
The known acute complications of myo-pericarditis include acute cardiac failure, arrhythmias, 
cardiac tamponade and sudden cardiac death (4, 49). The longer-term complications include 
chronic heart failure, dilated cardiomyopathy and chronic pericarditis, which may be constrictive 
in nature (4, 6, 49). 
 
2.3.3.4.  Sudden cardiac death (SCD) in athletes and myo-pericarditis  
 
Animal studies 
Most of the experimental studies relating acute myo-pericarditis and exercise were conducted in 
mice inoculated with coxsackie viruses. In these studies, it has been shown that exercise stress in 
young and adult mice increased inflammation, tissue damage and necrosis. Acute infectious 
myocarditis was associated with cardiac and skeletal muscle protein breakdown, and viral 
replication rates were also increased in the suckling mice (49). Exercise stress has been associated 





In general, the reported incidence of SCD in young athletes varies between 1:44 000 and 1:300 
000 (56). Male gender appears to be a risk factor (♂:♀ ratios vary from 5:1 – 9:1) (56), and 
certain race groups e.g. African-American athletes, appear to be at increased risk (56). In a recent 
review, it has been reported that myocarditis is responsible for 7% of SCD in athletes (56). 
However, this may vary between 5 and 22% (10).    
 
In one review of sudden unexpected death in 16 young Swedish orienteers before 1992, it was 
documented that sub-acute / chronic myocarditis was the most frequent finding on 
histopathology. In this study, near-maximal exercise was implicated in death in all but 2 cases, 
but only 5 of these cases had reported cardiac symptoms prior to their death (49). These data 
support the hypothesis that exercise can aggravate sub-clinical (asymptomatic) myocarditis. A 
case control study reported that a history of a flu-like illness or fatigue in the previous month 
increased an athlete’s odds ratio to 13 for having an acute cardiac event during exercise (57). It 
must be emphasized that in the majority of cases, myo-pericarditis resolves without sequelae if 
properly managed and that SCD is a rare event (49). However, from a clinical point of view, it is 
important to exclude myo-pericarditis before advising an athlete to continue with exercise 
training or competition. 
 
2.3.4.  Exercise-related medical complications of Infectious 
Mononucleosis 
 
The athlete with acute infectious mononucleosis (IM) may present a particular challenge to the 
SEM physician. There are several serious medical complications that are associated with IM. The 
well-documented complication is that of splenic rupture, which may be associated with exercise. 
Other complications include aplastic anaemia, Guillain Barré Syndrome, meningitis and 
encephalitis, neuritis, lymphoma, haemolytic uraemic syndrome and disseminated intra-vascular 
coagulation (DIC) (3). An uncommon complication is airway compromise secondary to tonsillar 
enlargement. It should be noted that up to 30% of patients with IM have a positive throat culture 
for GABHS.   
 
Splenomegaly is common in patients with IM, with reports of prevalence ranging between 50% 
(7) and near 100% (3). Splenic rupture is a known, but rare complication of IM, with an estimated 
incidence of 0.1%-0.2% (3, 33). Splenic rupture may occur with or without co-incident direct 
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trauma (3). A review of 55 cases of splenic rupture showed that almost half occurred 
spontaneously, thought to be as a result of sudden increases in portal pressure secondary to a 
Valsalva manoeuvre (3). Of note was the fact that almost all ruptures occurred in male patients 
between day 4 and day 21 of infection (33). It is rare that rupture occurs after 4 weeks of 
infection, indicating that the first 4 weeks constitute a time of increased vulnerability (3).   
 
Clinical examination has limited reliability in detecting splenomegaly (3, 10, 28). Data are limited 
regarding normative values in athletic populations, some of whom have been shown to have 
larger spleens than average (an upper limit of normal longitudinal size quoted as 12-14cm) (3).   
 
2.3.5.  Risks of medical complications during exercise while suffering 
from acute gastro-intestinal illness  
 
Acute gastro-intestinal illness, presenting as nausea, vomiting and diarrhoea, is one of the most 
common acute medical illnesses in athletes. The SEM physician frequently makes a clinical 
decision on return to play following acute gastro-intestinal illness and therefore the risk of 
medical complications related to these illnesses is important. Gastro-enteritis may cause 
dehydration, which in turn may cause electrolyte imbalances and contribute to the development of 
acute renal failure. Acute diarrhoea is often associated with significant intestinal secretion of fluid 
(especially Entero-toxigenic E. Coli) (47) and these fluid shifts may be associated with hypo- or 
hypernatraemia, in combination with hypokalaemia (58, 59). Vomiting may also cause a 
metabolic alkalosis. Changes in ADH levels (related to possible fever as well as fluid shifts) will 
have consequent effects on serum electrolyte concentrations.   
 
Additionally, the use of medications to provide symptomatic relief in gastro-enteritis may also 
affect endurance exercise. Anti-spasmodics and anti-motility agents may affect thermoregulation 
(40), while medications such a loperamide may reduce the passage of diarrhoea, but do not stop 
the intestinal fluid secretion associated with the illness, thus facilitating a ‘hidden reservoir’ of 
lost fluid. This may have implications for fluid homeostasis and thus electrolyte abnormalities.  
 
However, to our knowledge, there are no studies that specifically relate the risk of medical 
complications to exercising with acute gastro-intestinal illness in athletes. This is a research area 
that requires urgent attention as RTP guidelines are needed to improve the safety of athletes.  
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2.3.6.  Acute illness and other potential medical complications during 
exercise 
 
There are a few additional considerations where acute illness during exercise may result in 
medical complications. Viral infections have been implicated in the development of exertional 
heat stroke (EHS). The evidence to support this hypothesis comes from two studies that are 
mentioned in the ACSM Statement on Exertional Heat Illness (60). In one study, 179 ‘heat 
casualties’ from a 14 km race were documented over a 9-year period: 23% of these runners 
reported a recent gastro-intestinal or respiratory illness. In the second study, 10 military recruits 
with EHS were described: 3 had a fever, while 6 had at least one impending sign of illness prior 
to collapse.  
 
Viral illness has also been associated with the development of acute renal failure (ARF). It 
appears that the ‘perfect storm’ of conditions may be required for the development of ARF in 
athletes – a combination of heat stress, dehydration, recent infection, the use of NSAIDs 
specifically and possible latent myopathies unmasked by the previous-mentioned factors (61). 
There is also evidence that systemic illness may cause non-exercise-related rhabdomyolysis when 
unmasking a latent myopathy (62). 
 
2.3.7.  Medical complications while exercising with acute illness: the risk 
of acute illness transmission  
 
One of the considerations in allowing an athlete to RTP, is how contagious they may be, and 
whether this would present a danger to other athletes. The three main types of infection seen in 
tournament settings would have remarkably different transmission methods: URTI via droplet or 
person-person spread (33); gastro-intestinal infection via faecal-oral transmission and consequent 
poor hygiene / hand-washing practice, or via fomites (63); skin infections such as herpes 
gladiatorum require direct contact. These facts should be considered in a team setting to prevent 






2.4. Potential effects on performance when exercising with an 
acute illness: a review 
 
Apart from the risk of medical complications, acute illness may also have negative effects on 
exercise performance. These data are important in athlete education and for coaching staff, and 
although this is not the focus of this dissertation, this aspect will be briefly reviewed.   
 
2.4.1. Reduced performance related to infection 
 
There are very few studies where exercise performance during an acute illness has been studied. 
This is obvious, as there is an ethical issue in performing these studies in humans, given the 
potential risk of acute medical complications during acute illness. In one study, experimental 
inoculation of rhinovirus into a healthy college population showed no reduction in pulmonary 
function, VO2 max and sub-maximal exercise capacity (50). Rhinovirus is responsible for up to 
40% of URTI episodes, making it the most common pathogen (40). Rhinovirus does not usually 
cause a febrile illness and is usually responsible for localised URTI symptoms. There were some 
early data to suggest that rhinovirus may cause transient changes in airway reactivity, but these 
were not clinically significant (64). However, rhinoviruses have been implicated in 60% of 
exacerbations of “viral” asthma and 59% of exacerbations of “viral” COPD (65), and acute 
exacerbations of asthma and COPD would have an effect on athletic performance. Systemic 
infection with influenza viruses is also associated with reductions in pulmonary function (28). In 
one unpublished study from the 2006 South African Iron Man triathlon, it was shown that 
respiratory tract symptoms in the 6 weeks prior to the race (especially lower RTS and systemic 
symptoms) had a significant effect on reducing training volume, and this resulted in slower race 
times (66). 
 
In summary, there are very few studies in this field. Those studies that are published are not 
conclusive. To date, to our knowledge, there is no published data that differentiate between 
localised and systemic pre-race respiratory tract symptoms and how these symptoms impact on 





2.4.2. Acute illness, bronchial hyper-reactivity and reduced exercise 
performance  
 
Athletes may present with wheezing after an upper or lower respiratory tract infection (67) and 
this is a syndrome known as WARI (wheezing after respiratory tract infection). It has been 
suggested that WARI may potentially have a significant impact on exercise performance in a 
subset of athletes. It has been documented that up to 40% of patients with community-acquired 
pneumonia and bronchitis demonstrate transient obstructive airways disease, with a decreased 
FEV1. These changes usually last for 3 weeks but can last for up to 2 months (4). However, we 
are not aware of any data specifically linking WARI to reduced exercise performance in athletes. 
Most athletes who present with new onset wheezing in a sports setting will have exercise-induced 
broncho-constriction (EIB) or previously undiagnosed asthma. The incidence of EIB is increased 
in the athletic population, especially in winter endurance sports such as Nordic skiing and speed-
skating, as well as swimmers and summer endurance athletes such as cyclists (35). It has been 
shown that WARI is increased in athletes whose sports require high minute ventilation rates, 
which include the above-mentioned sports. However, whether the pathophysiology of WARI is 
linked to that of EIB and whether this affects performance, is an interesting topic for further 
study. One study reported an increase in bronchial reactivity in Nordic skiers after a RTI, when 
compared to non-exercising controls and the conclusion was that the exercise was the responsible 
mechanism (68). However, this particular subset of athletes is known to be more prone to 
bronchial hyper-reactivity (35). It is therefore unclear whether the increased bronchospasm was 
due to infection or the EIB predisposition in the skiers, or a combination of the two.  
 
Organisms that have been implicated in WARI include the ‘atypical pneumonias’ as well as viral 
infections. Chlamydophila pneumonia has been found to be associated with post-infectious 
reactive airways in all ages (67). There is conflicting evidence of WARI leading to permanent 
obstructive changes (67). Mycoplasma pneumonia has also been associated with WARI in 
children and adults, as well as asthma recurrence (67). In such atypical infections, macrolide 
antibiotics appeared to have role in the treatment of WARI, as macrolides have an anti-
inflammatory as well as antibiotic effect. However, macrolides have been found to prolong the 
QT interval, thus increasing the risk of SCD in exercise (7). Viral URTIs can cause wheezing and 
acute exacerbations in asthmatics, but little evidence exists for this phenomenon in non-
asthmatics. The study of rhinovirus inoculation into healthy volunteers showed no changes in 
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pulmonary function (69). However, this may be virus-specific. RSV is known to cause wheezing, 
but only in those under the age of 2.  
 
2.4.3. Athlete withdrawal from competition as a consequence of acute 
illness 
 
An athlete may withdraw from competition as a result of an acute illness. This decision may be 
made by the athletes themselves, the coach or based on medical advice that an athlete obtained. 
The days lost as a result of acute illness (time-loss illness) has been reported in some studies. In 
several multi-day tournaments, the proportion of illness causing a time-loss of ≥1 day has been 
reported to be between 26 and 45% (21-25, 31). Therefore, the proportion of time-loss illnesses in 
multi-day tournaments is significant for an athlete.  
 
There is not much literature available regarding withdrawal from single events due to illness.  
However, there are 3 studies of pre-race ‘drop-outs’ in marathons in the 1980’s: the first two 
reported data from the Aberdeen Milk Marathon, and the third from the Glasgow marathon. The 
first study reported that illness was responsible for 16% of 502 drop-out responders (response rate 
of 43%). In this study, a third of runners indicated they would have run a half-marathon if it was 
an option (70). The second study reported that 12% of drop-outs were as a result of illness, and 
73% of these runners decided not to run in the week before the race (71). The third study reported 
that 46% of drop-outs were due to ‘ill-health’, which included injury and illness (72). However, 
in none of these studies was an absolute pre-race drop-out rate reported, as they were based on 
samples including runners who started and those who did not.   
 
2.5. Decision Modifiers for RTP guidelines 
 
Decision modifiers are only relevant when the participation risk has been ascertained. Modifiers 
are external influences on the SEM physician’s RTP decision, and may increase or decrease the 
participation risk for a specific athlete with a given health status (1). Traditionally, modifiers in 
the literature have applied to RTP after injury and include the type of sport e.g. lawn bowls does 
not have the same aerobic requirement as marathon running. The level of competition (amateur 
vs. professional) has been cited as a modifier, as has the importance of the specific event (finals 
vs. heats etc.). However, these latter factors should not be considered modifiers in serious 
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musculokeletal injury or acute illness. External pressure may also come from coaches and family 
members, as well as from the athlete themselves (1). 
 
2.6. Available RTP guidelines 
 
Participation guidelines should be able to identify when the athlete is safe to return to training 
following an illness or an injury. There should be guidance as to the progression of intensity, 
dependent on symptoms, as well as an indication of when the athlete should be ready to return to 
competition. The potential risks of exercising while acutely ill have already been discussed.  
Current recommendations for RTP after acute illness were recently reviewed (7).  
 
Despite the fact that there are several published guidelines regarding RTP in acutely ill athletes, 
there are relatively few clinical and research data to support these guidelines. Specifically, for 
URTS, which are one of the most common reasons for presenting to SEM physicians, the 
evidence is to support current RTP guidelines is minimal. Most SEM physicians are guided by the 
‘neck check’, which was first described in 1993 (73). The ‘neck check’ is based on self-reported 
symptoms of acute illness. The RTP guidelines for URTI have since evolved from this first 
recommendation (7, 8, 28, 33, 42, 49, 64).   
 
In the literature, there are clear evidence-based RTP guidelines available for specific acute 
illnesses such as myocarditis and infectious mononucleosis (3-8). These guidelines are relevant to 
the SEM physician as IM is a differential diagnosis for a sore throat / exudative pharyngitis, and 
myocarditis is a well-publicised risk of exercising whilst ill. However, as mentioned, there are 
few studies to support the clinical guidelines as outlined in the neck check. Therefore, the basis of 
the neck check will be reviewed.  
 
2.6.1.  The history of the ‘Neck Check’ clinical guideline 
 
The ‘neck check’ guideline was originally proposed in 1993, following a review of the available 
evidence, mainly from the exercise immunology literature. These data consisted of studies 
describing the exercise-related changes in immune parameters (73).  In this review, the following 
main conclusions were made: 
1. Exercise-related immune changes include an immediate elevation of neutrophils and 
lymphocytes, mediated by adrenalin. Thereafter a further rise in neutrophils (more in 
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strenuous exercise) and delayed fall in lymphocytes is seen (cortisol- mediated). NK cell 
activity and numbers rise during strenuous activity and fall afterwards, returning to normal 
limits by 24 hours (adrenalin and interleukin-mediated). Decreased concentrations of salivary 
IgA are seen after strenuous / prolonged exercise. It was recognised that these changes could 
not be causally associated with clinical infections in athletes, but it was hypothesised that the 
transient drop in immunity after strenuous exercise may predispose the athlete to developing 
an URTI. 
2. Due to adverse physiological effects of a fever, it was not advisable to exercise with a fever. 
3. It was noted, quite rightly, that in the acute phase of an illness, one could not be sure whether 
the illness would turn into a “harmless URTI, incipient mycoplasmal pneumonia or a virus 
with a propensity to cause myocarditis”. Additionally, it was emphasised that training in this 
state would have no benefits, thus REST was advised. 
4. Finally, “tentative and arbitrary guidelines” were grudgingly offered for those elite athletes 
who believed they could not miss a day’s worth of training. This advice was the ‘neck check’.  
For symptoms ‘above the neck’ e.g. runny or congested nose, sneezing or scratchy throat: an 
athlete could cautiously begin the workout at half speed. If feeling well after 10 minutes, one 
could complete the workout; if not, the athlete was advised to stop and rest. For fever and 
symptoms ‘below the neck’ e.g. “myalgia, a ‘hacking’ cough, diarrhoea or vomiting”: 
exercise was not advised. 
 
2.6.2.  Current evidence to support the ‘Neck Check’ clinical RTP 
guideline 
 
The evidence underpinning the neck check clinical guidelines was reviewed 20 years ago and has, 
to our knowledge, not been reviewed since. Therefore, in the next section of this review Chapter, 
more recently published evidence to support the neck check guidelines will be reviewed as 
follows:  
 Evidence that it is safe to exercise with localised upper respiratory tract symptoms 
 Evidence that there is an increased risk of medical complications during exercise with fever 
or symptoms ‘below-the-neck’ 




2.6.2.1.  Evidence that it is safe to exercise with localised upper respiratory tract symptoms - 
symptoms ‘above-the-neck’ 
 
To our knowledge, the study of iatrogenic rhinovirus infection is the only clinical study that 
supports the hypothesis that it is safe to exercise with localised upper respiratory tract symptoms. 
In this study it was reported that exercise stress had no ill effects on severity scores in the subjects 
(50), and that there was no reduction in pulmonary function (69). This may apply to a rhinovirus 
infection, which is the most common cause of URTI. However, there are no other data relating to 
any of the other commonly implicated viruses or other micro-organisms causing URTI. 
Therefore, with regard to exercising with localised URT symptoms, further evidence of safety is 
required. However, absence of such evidence does not imply evidence of risk.   
 
There are specific concerns about using a symptom-based ‘neck check’ only. An athlete with a 
sore throat may have early GABHS or IM. In the case of GABHS: some authors’ 
recommendations included clear restriction from play, and suggested rest for the first week of 
illness, whilst ingesting antibiotics (49). This recommendation was presumably based on the risk 
of myo-pericarditis from GABHS. Some recommendations allow RTP after at least 24 hours of 
antibiotics and resolution of fever (74). However, diagnosis of GABHS requires clinical 
assessment, and can rarely, if ever, be diagnosed on history alone. IM may also present with only 
a sore throat. Again, clinical assessment is required to make the diagnosis, and a diagnosis of IM 
cannot be made on history alone. Furthermore, in the case of IM, RTP guidelines are even more 
restrictive than those for GABHS.   
 
2.6.2.2.  Evidence that there is an increased risk of medical complications during exercise with 
fever or symptoms ‘below-the-neck’  
 
The risk of medical complications during exercise in athletes with acute infections has already 
been reviewed (Section 2.3). In summary, there is some evidence that fever and symptoms of 
systemic infections are associated with an increased risk of medical complications during exercise 
as follows:  
 Fever:  
The adverse effects of fever include metabolic, cardiovascular, musculoskeletal and 
neuromuscular changes. Increased insensible water losses are seen, together with dehydration 
and temperature dysregulation (8). 
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Metabolic changes: these include increased serum levels of adrenaline, causing an increased 
resting heart rate, a raised metabolic rate and peripheral vasoconstriction. Increased insulin 
secretion results in lower serum glucose levels (49). ADH levels are reduced, causing 
increased insensible water losses (8); however, LRTI may cause increased ADH (75).   
Cardiovascular changes: these include a tachycardia, reduced stroke volume and aerobic 
capacity, with some evidence from animal studies suggesting that cardiovascular conditioning 
may attenuate the reduction in aerobic capacity (49). 
 
 Myalgia: 
Myalgia is indicative of a muscle dysfunction (40, 49) and may be associated with myositis 
(76, 77). This may increase the risk of myocarditis, and rhabdomyolysis (61, 62). Reductions 
in speed, concentration, co-ordination and precision have been noted in febrile illnesses, most 
evident in days 3-4 of infection (49). 
 
 Sub-clinical myocarditis: 
Exercise may aggravate sub-clinical myocarditis, which may be asymptomatic from a cardiac 
perspective (49). 
 
 Influenza infection (a systemic illness): 
Influenza infection is associated with a reduction in pulmonary function (28). Animal studies 
with influenza infection showed increased lethality in the acute phase (8). It is unclear 
whether the risks are a function of the organism, or the systemic nature of the illness. 
 
 Gastro-enteritis:  
The potential risk of medical complications during exercise in athletes with gastro-enteritis 
has been reviewed in Section 2.3.5. These risks include dehydration and electrolyte 
abnormalities, as well as the effects of the medications commonly used in these infections.   
 
 LRT symptoms: 
The presence of a fever may be a guide to diagnosing pneumonia, but there are no published 
data that we are aware of which detail the risks of exercising with LRTI. However, exercise is 
a known aggravating factor in asthma, and increased bronchospasm and dyspnoea could 
therefore be expected when these athletes develop a LRTI. In an athlete presenting with a 
productive cough, but no systemic symptoms, a diagnosis of bronchitis (mostly of viral 
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origin) has to be considered. However, there is no evidence that reports on the effects of 
exercise in bronchitis (42). As mentioned previously (Section 2.4.2), some athletes with 
LRTS may have WARI, but there is no data as yet to indicate whether exercising with WARI 
is safe, or whether it affects performance. Further studies are required in this field.  
 
2.6.2.3.  Evidence regarding the timescale for RTP after acute illness 
 
There are few clinical and research data concerning a safe timeframe for RTP. Instead, there has 
been an evolution of current recommendations regarding the timescale for RTP following an 
acute illness. This can be summarised as follows: 
 It has been shown that illness may be exacerbated if an athlete exercises in the acute infective 
stage (51). Therefore, in 1996, it was suggested that training be reduced for 2-3 days before 
intense exercise is resumed in patients who feel they are getting ill, in order to prevent 
aggravation of the illness (40).  
 In 2000, these recommendations were consolidated in a statement indicating that serious 
illness often has prodromal symptoms and may take 2-3 days to declare itself (49).   
 In 2007, clinical data were published to support this recommendation. In this study, it was 
documented that symptom and functionality scores were significantly lower on days 3-4 in 
triathletes in whom an infective organism had been identified (16). 
 
2.6.3.  Summary: Evidence to support current recommendations 
regarding RTP guidelines for athletes with acute illness  
  
In this section, data that are relevant to RTP guidelines for athletes with acute illness have been 
reviewed. It is clear that there are very few clinical or laboratory studies in this field. Despite the 
lack of clinical data, there have been many published recommendations, including position 
statements by the British Association of Sports and Exercise Science (BASES) in 2005 (78, 79) 
and the more recent International Society of Exercise and Immunology  (ISEI) in 2011(10).  
 
The following is a summary of the current recommendations on RTP guidelines for athletes 
with acute illness, since the original neck check was proposed more than 20 years ago:  
 
 In athletes presenting with initial symptoms of illness, the presence of a fever or any systemic 
symptoms such as arthralgia, myalgias, headache, diarrhoea or vomiting should preclude  
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them from any exercise (10, 78). 
 Athletes should refrain from strenuous exercise in the early phase (first day) of infection, and 
may gradually increase their intensity over a few days if their symptoms remain ‘above-the-
neck’ (e.g. runny nose, scratchy throat). Athletes should preferably exercise alone to prevent 
transmission of the illness (10, 78).  
 It was recommended that a temperature of 0.5 - 1°C higher than normal baseline, together 
with a heart rate of 10 beats per minute above the normal resting HR, as well as systemic 
symptoms (fatigue, muscle tenderness or pain, arthralgia or headache) all indicate that the 
athlete should rest from exercise until systemic symptoms have resolved (49). This statement 
presumes that the athlete knows their resting HR and baseline body temperature. It has been 
suggested that athletes measure their resting HR, as there is some evidence in swimmers that 
an increase in both supine and standing values may indicate the onset of an illness (41).   
 Athletes should present early to their team physician if part of a team, or travelling, for the 
benefit of their own and the team’s health (21). 
 The diagnosis of GABHS pharyngitis precludes the athlete from participation, for between 1-7 
days, depending on the recommendations followed (49, 74).  
 Athletes with influenza should refrain from exercise for at least 5 days (to allow for 
infectivity to clear), before returning at light intensity exercise. This RTP is dependent on the 
absence of fever for at least 24 hours and the resolution of systemic symptoms (4, 79). 
 Athletes with confirmed or suspected pertussis should be isolated for the first 5 days after 
symptoms begin (4).   
 In the return to exercise training, it should take as many days as the athlete was not training, 
to increase exercise intensity to the pre-illness level (10, 64, 78). 
 In the case of athletes with URTI or GI symptoms, the athlete has to be free of fever for at 
least 1 day following the URTI / GI symptoms before light exercise may be undertaken (10, 
78).   
 For gastro-intestinal infection, RTP may only be considered once symptoms and fever have 
resolved and body weight is normal or near-normal after adequate rehydration. If blood tests 
were done, serum electrolyte concentrations, haematocrit, liver function and inflammatory 
markers must all have returned to normal (7, 10, 78). 
 If returning to exercise post-URTI and exercising in temperatures of < -10°C, cold air 
protection should be used for at least a week, to prevent any aggravation of WARI (10, 78). 
 If initial symptoms worsen, fever recurs, cough worsens or breathing problems arise during 
exercise, a medical opinion should be sought (10, 78).  
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 Inflammatory markers must return to normal before RTP is considered (7).  
 A resting ECG is advised before RTP when an athlete used a macrolide antibiotic – this is 
due to the risk of prolonged QT Syndrome with these antibiotics and consequent risks of SCD 
during exercise (7). 
 The ISEI statement also includes a recommendation for any elite athlete with a non-specific 
URTI to not exercise for 4 weeks afterwards, with a view to preventing myocarditis. It 
recognizes that this recommendation will rarely be followed, but urges the clinician to have a 
high index of suspicion of myocarditis in the spring or summer, when viral infections such as 
Parvovirus B19, Echovirus, coxsackie virus and Herpes Virus 6 are more prevalent (10). 
 There are inadequate data regarding RTP after LRTI, including bronchitis, with a general 
recommendation to see a physician to ensure full resolution of symptoms (4, 7, 55, 75). 
Following the ISEI guidelines, athletes may only RTP once their fever and systemic 
symptoms resolved (4, 7, 55, 74, 75). In the case of WARI, there is no evidence as yet to 
indicate safe parameters for RTP. There are some guidelines for RTP after EIB, but these 
only apply to those athletes who develop EIB acutely during exercise (80).   
 There are clear recommendations for athletes returning to play after a diagnosis of IM in 
order to reduce the risk of splenic rupture. These guidelines have been extensively described 
in the literature (3, 7, 10, 28, 33).    
 The 36th Bethesda Conference gives clear recommendations for a minimum of 6 months off 
competitive exercise before RTP following a diagnosis of myocarditis and pericarditis (5). 
The previously mentioned study of SCD in young Swedish orienteers reported a marked 
reduction in SCD after 1992, at which time the 6-month exclusion recommendations were 
introduced (49). 
 
In summary, several authors or official bodies have provided guidelines on RTP for athletes with 
acute illness. However, this review shows that these guidelines are an extension of the original 
‘neck check’, with few recent clinical or laboratory studies to support the current guidelines. 
There are very few data to support the safety of exercise with a localised URTI; however, the 
near-absence of evidence of safety does not imply evidence of risk and further studies are 
therefore indicated. Excluding the clinical data regarding myocarditis and splenic rupture in IM, 
there are few clinical data examining the risks of exercising with LRT or systemic symptoms. 
 
It is also clear from the review that a RTP guideline cannot be used on the basis of a patient’s 
reported symptoms only. At the very least, a clinical assessment (including a physical 
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examination) is essential for these guidelines to be implemented safely. Athletes should be 
examined at the initial assessment, as well as before RTP to ensure that clinical resolution of 
symptoms has occurred. 
 
2.7.  Summary  
 
In summary, the aim of this literature review was to establish the evidence base behind current 
return-to-play (RTP) guidelines for athletes with acute illness.   
 
There are no clinical data to correlate the exercise-related changes in immune parameters with 
symptoms of upper respiratory tract infections commonly seen in athletes. There are few data 
pertaining to pre-competition prevalence of acute illness. The available evidence refers to the 
incidence rate of illness in tournament settings, where symptoms of URTI are very common, 
followed by gastro-intestinal and skin infections. Post-race URT symptoms may be related to pre-
race symptoms, which may not be infective in origin, and allergy needs to be considered as one of 
the possibilities.    
 
Possible risk factors for acute illness in the pre-competition period included an increased training 
load, where a ‘J-curve’ and ‘S-curve’ have been described with reference to URTS in elite and 
high-load athletes. There are no conclusive data regarding the effect of gender on illness risk, 
although some studies show a slight increased risk in females. Similarly, some studies show no 
difference in risk associated with age, whereas others report an increased risk with older age.  
Travel has been reported to increase the risk of infection, with closer proximity of team-mates, 
food-borne gastro-enteritis and other unknown factors at destinations more than 5 hour time 
zones away from home, being cited as risks. Allergy is a documented risk factor for URTS, as is 
environment, with cold-weather sports with high ventilation volumes being at significant risk. 
Different sporting codes have reported differing incident rates of illness.   
 
Current recommendations regarding RTP following acute illness refer to symptomatology only. 
The contribution that a clinical assessment would provide in the RTP decision-making process 
was discussed. The clinician has an important role in interpreting symptom complexes, whilst 
considering allergy as a differential diagnosis in URTS. Objective parameters on examination 
were described with respect to infection, such as increased body temperature and heart rate. 
Clinical assessment is poor at differentiating infective from non-infective symptoms, and it is 
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difficult to differentiate between bacterial and viral infections. Laboratory investigations may 
improve this process, but most of the investigations are non-specific for infection vs. systemic 
inflammation e.g. ESR and CRP. Research is being directed at novel biomarkers of infection e.g. 
PCT, but these mostly target sepsis, which is bacterial in nature. Currently, there are no 
biomarkers that differentiate between inflammation, viral infection and bacterial infection.   
 
There is evidence for the potential complications of exercising with symptoms of acute infection.  
SEM physicians need to be aware of this information to be able to make an informed decision 
regarding safe RTP. There are some clinical data documenting the adverse effects of fever: these 
include metabolic, cardiovascular, musculoskeletal and neuromuscular changes. Additionally, 
increased insensible water losses occur, resulting in possible dehydration. Temperature 
dysregulation occurs with febrile illness. These changes all put the febrile exercising athlete at 
risk for complications. Other potential medical complications include exacerbation of the illness, 
possibly related to the timing of exercise with respect to timing of inoculation. Furthermore, there 
is a risk of sudden cardiac death when exercising with myo-pericarditis. When exercising with 
IM, the main risk is splenic rupture, seen mostly in males in the first 3 weeks of infection. Other 
potential complications include dehydration and electrolyte disturbance in gastro-enteritis and 
viral illness may increase the risk of acute renal failure and exertional heatstroke.   
 
There are few data regarding acute illness and performance, but some data do suggest that 
performance may be sub-optimal in athletes with acute illness, either due to the illness itself or 
sequelae such as WARI. A significant adverse effect of illness on performance is the potential 
withdrawal from competition.   
 
Finally, all the available evidence was correlated with the current recommendations on RTP after 
acute illness, the so-called ‘neck check’. The original recommendations by Eichner were 
examined – these were based on studies detailing immune changes in athletes after exercise, as 
well as those physiological changes seen with fever. Each aspect of his recommendations was 
evaluated as to whether there have been any further contributions in the literature, which support 
or refute his advice. To date, there is only one clinical study to support the safety of exercising 
with a localised URTI i.e. ‘above the neck’ symptoms, caused by rhinovirus. There are no clinical 
data to suggest that exercising with such localised URTI symptoms is associated with an 
increased risk of medical complications. There is some evidence to support the hypothesis that 
exercising with systemic or ‘below-the-neck’ symptoms poses a wide variety of risks to the 
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athlete. By necessity, many of these data are epidemiological in nature, and there are few clinical 
studies. Despite this lack of data, many authors and official bodies have published guidelines, 
each of which is an extension of former recommendations, with little new data to support them.  
In the last 20 years there is little additional evidence to support the use of the ‘neck check’ as a 
participation guideline in athletes after acute illness. Infectious mononucleosis and myo-
pericarditis are the only conditions where clearer, evidence-based RTP guidelines are available.   
 
It has therefore clear that there is insufficient evidence to address many of the questions that were 
raised in the Introduction section of this dissertation. Therefore, a prospective study was 
undertaken in a cohort of runners who presented with acute illness before a distance running 




Chapter 3: Original research study 
 
Illness, adherence to medical advice, and participation data in 
242 endurance runners presenting to a Pre-Race acute Illness 
Medical Assessment (PRIMA) facility – a prospective cohort 
study 
 
3.1.  Introduction  
 
In Chapter 2, the relationship between acute illness and exercise was reviewed, specifically with 
the view to provide safe participation advice to an athlete with symptoms of acute illness. There 
is good evidence that symptoms of URT illness constitute the most common reason for medical 
consultations in SEM clinics (16, 47), as well as in tournament settings (20-24, 31). These 
symptoms may not always be infective in origin and a different aetiology such as allergy should 
be borne in mind (12, 13, 16, 18). Training load (16, 26, 29, 30), environment (24, 35, 36), travel 
to a distant country (32) and allergy (17) have been identified as significant risk factors for such 
symptoms.  
 
There is also a risk of acute medical complications during exercise in athletes with an acute 
illness. It is essential to determine this risk, and provide safe participation guidelines (1). The risk 
of medical complications is related to a number of factors including the nature of the illness 
(localised or systemic symptoms), presence of fever (8), the risk of myocarditis (52, 54), and 
possible splenic rupture up to 4 weeks following infection with infectious mononucleosis (3, 33). 
Furthermore, there is scant clinical evidence in humans regarding the effect of exercise on the 
course of illness (50), and there are few clinical data examining the effect of acute illness on 
exercise performance (66). In some studies, time-loss as a result of acute illness has been 
documented (21-25, 31). 
 
Currently, the RTP guideline for athletes with acute illness is the ‘neck check’. The available 
evidence supporting the neck check as a participation guideline in athletes with symptoms of 
acute illness, both in terms of its validity and application has been reviewed (Chapter 2). From 
this review, it is clear that there are minimal data supporting the safety of exercising with 
localised URT infection, i.e. ‘above-the-neck’ illness (50, 69). There are some data to support the 
potential risks of exercising with ‘below-the-neck’ illness (8, 28, 64). The only clinical data 
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regarding a timeline for RTP suggest that functionality and symptom scores are lowest on days 3 
and 4 in athletes with proven infection (16). To our knowledge, there are no studies examining 
the application of the neck check principles for guiding safe participation; neither are we aware of 
any studies exploring what happens to athletes who participate when they do have a clinical 
diagnosis suggesting acute illness.   
 
We are also not aware of any data documenting the point prevalence of acute illness (based on 
clinical examination) before an endurance event. In previously published studies, the prevalence 
of symptoms of illness before athletic events has been based on self-reported symptoms only (15, 
17, 30, 81). However, there is evidence that a physical examination of an athlete with symptoms 
of acute illness is important to make an accurate diagnosis and thereby optimise management 
(Chapter 2).   
 
The Old Mutual Two Oceans Marathon takes place in autumn in Cape Town, South Africa. A 
56km ultra-marathon and half-marathon are the main events, with trail runs of 10 and 21km 
offered as smaller events, together with a 9-10km fun run. In 2012, a pilot project was undertaken 
whereby elite and recreational half-marathon and ultra-marathon runners could obtain free 
medical advice at a Pre-Race acute Illness Medical Assessment (PRIMA) facility during race 
registration in the 3 days prior to the race. The feasibility for runners to be assessed clinically and 
then advised on safety to participate was tested in this pilot project. The PRIMA was based on a 
modified ‘neck check’, as summarised in the current RTP guidelines (7, 9, 49, 73, 78). Athletes 
were given advice, based on a medical history only, or a medical history and a physical 
examination. Based on the outcomes of this pilot project, we planned this study to investigate the 
athletes with pre-race symptoms of acute illness, the use of the neck check as a participation 
guideline as well the tracking of such a cohort with respect to race participation, race completion 
and possible medical complications during exercise. 
 
3.2.  Aim of the study  
 
The aim of this study was to 1) document the type and prevalence of acute illness in runners 
presenting to a Pre-Race acute Illness Medical Assessment (PRIMA) facility in the 3 days before 
a race, 2) determine adherence to advice given by medical staff to runners with acute illness, 3) 
determine the effects of the outcomes of the medical assessment on the ability to finish the race, 
and 4) determine the effects of the outcomes of the medical assessment on medical complications 
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during the race.  These data are important to improve the medical care of runners (and other 
athletes) presenting with acute illness before training and competition.  
3.3.  Methodology 
3.3.1.  Type of study 
This was a prospective cohort study. 
3.3.2.  Pre-Race acute Illness Medical Assessment (PRIMA) facility 
A ‘Medical Village’ at the compulsory registration venue provided an opportunity to establish a 
Pre-Race acute Illness Medical Assessment (PRIMA) facility, where runners, who were 
concerned about symptoms of acute illness, could be assessed free of charge.   
The PRIMA facility was advertised in educational health emails that were sent out to all 
registered runners in the 3 months before the race, as well as in the event magazine. In 2013, a 
pre-race information booklet regarding acute illness was sent by email to all registered runners in 
the week preceding the race. The email invited them to the medical facility in case they had any 
concerns regarding acute illness. In 2014, runners received a text SMS message 6 days and again 
4 days before the race, inviting them to the medical facility in case of any concerns regarding 
acute illness. Staff at the registration venue could also direct runners to the medical facility. 
Several runners with symptoms of acute illness were also sent to the medical facility from the 
main sponsor’s stall, where free ‘wellness checks’ for blood pressure, cholesterol and glucose 
were on offer. The PRIMA facility was open for the duration of the Registration Expo in the three 
days prior to the race and was also advertised in the registration venue, and was staffed by Sport 
and Exercise Medicine (SEM) physicians as well as nursing staff. 
3.3.3.  Pre-Race acute Illness Medical Assessment (PRIMA) 
Runners could present themselves to the PRIMA facility without an appointment. Upon 
presentation, staff screened all the runners (doctors only in 2013, and either nurses or doctors in 
2014). Screening consisted of obtaining demographic data, followed by obtaining a standardised 
medical history. A standardised physical examination was advised, if indicated by elements in the 
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history (see section 3.3.3.1. below). Runners were assessed 3 days before, 2 days before or 1 day 
before the race. All data were recorded on Samsung electronic tablets. Demographic information 
included the runner’s name, gender and unique race number, as well as the race for which they 
were registered. Details of the PRIMA are shown in Appendix A. 
 
3.3.3.1.  Medical history 
 
A medical history was taken with the focus on the runner’s main presenting symptom and any 
secondary symptoms. On the basis of this medical history, the runner was advised to undergo a 
physical examination. The presence of any one (or more) of the following symptoms triggered the 
advice that a physical examination is indicated: 
 Any systemic symptoms including a history of fever, myalgia, general body aches, excessive 
fatigue, malaise, arthralgia, or headaches.  
 Any lower respiratory tract symptoms including a productive or non-productive cough, 
wheezing, “tight” chest, chest pain or shortness of breath. 
 Any gastro-intestinal symptoms including abdominal pain, cramps, nausea, vomiting, or 
diarrhoea. 
 Any cardiac symptoms including chest pain, shortness of breath, or palpitations.   
 A sore throat. 
 Any runner requesting a physical examination. 
 
3.3.3.2.  Physical examination 
 
 Prior to a physical examination, informed consent was obtained. The physical examination was 
performed in a private area by one of the physicians. In 2014, the nurses performed the following 
vital sign investigations: aural thermometry (using one Braun aural thermometer), resting blood 
pressure, and resting heart rate. Following a general examination, a specific systemic examination 
was performed as indicated, and consisted of examination of the following systems: ear, nose and 
throat (ENT), respiratory, cardiac, abdominal, neurological or musculo-skeletal systems. All 
clinical data (medical history and physical examination) were recorded in the same file and stored 
securely. The final working diagnosis was recorded, together with any secondary diagnoses.  
 
Any runner with any upper or lower respiratory tract symptoms, gastro-intestinal symptoms or 
systemic symptoms (fever, fatigue, malaise, myalgia, arthralgia, general body aches, headaches) 
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were assessed. Symptoms of other localised infections were also included. Two clinicians decided 
if there was a possible infective component by reviewing the data from runners. Data included the 
symptoms as well as the working diagnoses recorded by the treating physicians. In cases where it 
was not clear that there was an infective aetiology, body temperature and heart rate were taken 
into account. Tympanic temperature was considered to be above normal if ≥ 37.5 °C in males, 
and ≥37.1 °C in females (as referenced in (82)). A resting HR of >75 was used as an indicator of 
possible infection, in the context of appropriate symptoms. A sinus bradycardia (<60 beats / min) 
is seen in up to 80% of trained endurance athletes (83) and the resting HR is known to increase by 
10-15 beats / min with illness (41). Where a discrepancy was noted between clinical findings and 
working diagnosis regarding infection as a possible aetiology, a working diagnosis was made by 
the treating clinician. Examination findings were evaluated for abnormalities that would suggest 
infection, or for changes associated with non-infective aetiologies such as allergies.  
3.3.3.3.  Diagnostic groups 
Following the PRIMA assessment, and based on the final clinical diagnosis, runners were 
therefore categorised into those with a clinical diagnosis of an infection (PRIMA infection group: 
PRIMA-I), or those runners with no evidence of an infection (PRIMA non-infection group: 
PRIMA-N/I).  
In the PRIMA-I group, diagnostic codes were assigned to each runner and categorised as either 
‘Localised’ (L) or ‘Systemic’ (S).  Localised URTI included: rhinitis (infected or not infected); 
pharyngitis; laryngitis; sinusitis and other localised infection. These illnesses were considered to 
be “above-the-neck” and constituted a ‘passed’ ‘neck check’. Where cervical lymphadenopathy 
was noted to be present with localised throat erythema, it was considered to be a localised 
pharyngitis that passed the neck check, as long as no exudate or systemic features were noted. 
The original ‘neck check’ advice made no mention of localised lymphadenopathy (73).   
Systemic illness included the following: URTI with systemic features; systemic infective illness 
(mostly ‘flu’-like illnesses); suspected myo-pericarditis; LRTI and gastro-enteritis. These 
illnesses were considered to be “below-the-neck” and constituted a ‘failed’ ‘neck check’. In cases 
where two diagnoses were recorded and both were localised infections, the primary diagnosis was 
used. However, if the primary diagnosis was a ‘localised’ illness and the secondary diagnosis was 
systemic in nature, the secondary diagnosis was used.  
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Runners with non-infective pathologies were assigned diagnostic codes indicating cardiac, 
musculoskeletal (MSK), lower respiratory tract symptoms of non-infective origin (LRTS) and 
‘Other’ pathology.  These runners comprised the PRIMA-N/I cohort. 
 
3.3.4.  Advice given to runners in the PRIMA group 
 
On completion of the PRIMA, medical staff gave runners advice regarding participation on race 
day. There were three main possible outcomes for the advice given to runners. For runners in the 
PRIMA N/I group, appropriate advice was given, based on their clinical diagnosis (non-
infective). In the PRIMA I group, the advice was based on the principles for current RTP clinical 
guidelines using the ‘neck check’.  
 
3.3.4.1.  Advice not to run (ANR) 
 
Runners were advised not to run on race day if they presented with “below the neck” or systemic 
features of illness, including any of the following: 
 Any systemic features of illness (fever, tachycardia, myalgia, excessive fatigue). 
 Any symptoms of gastro-enteritis, namely diarrhoea and vomiting, or clinical evidence of 
dehydration. 
 Any lower respiratory tract symptoms or signs, namely cough, wheeze, shortness of breath, 
chest pain, or any abnormal respiratory finding compatible with infection. 
 Pharyngitis suspected to be of GABHS origin (‘Strep throat’) including exudative tonsillo-
pharyngitis. 
 Any other condition, infective or otherwise, where the clinician felt it would not be advisable 
to compete. 
 
3.3.4.2.  Advice to monitor symptoms and handing out an information sheet with return to play 
information and guidelines (Info+MS group) 
  
As previously indicated, runners were assessed up to 3 days before the race. Therefore, runners 
who had symptoms more than 24 hours before the race were in some instances advised to monitor 
their symptoms, and then use the information and guidelines to decide on race day whether to 
compete or not.  These runners were given one or more of three educational information leaflets 
on ‘Exercise and acute illness’, ‘Exercise and URTI’ or ‘Exercise and gastro-intestinal infection’ 
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(Appendix B). The information in the leaflets was discussed so that the runner could make an 
informed decision on race day. This advice was based on the ‘above-the-neck’ symptoms 
mentioned in the neck check. 
 
3.3.4.3.  Advice that it is probably safe to participate, together with handing out an information 
sheet with return to play information and guidelines (Info only group) 
  
Runners who had very localised URTS, with no evidence of systemic features, were advised that 
it was probably safe to race. These runners were advised to see how they felt after the first 10-15 
minutes of the race, starting at a pace 50% slower than usual. If they felt fine, it was deemed safe 
to continue. However, they were advised to stop running and withdraw from the race if their 
symptoms deteriorated. All these runners were also given the same educational information 
leaflets (section 3.3.3.3), and this information was discussed with them.  
 
3.3.5.  Research Ethics and Informed consent 
 
This study formed part of a large prospective cohort study on reducing the risk of medical 
complications in endurance sports. This study is titled: “Medical consequences in endurance 
sports. Two Oceans Marathon longitudinal study: 2013-2015”. Research Ethics approval for this 
study was obtained from the Research Ethics Committee of the Faculty of Health Sciences of the 
University of Cape Town prior to starting the study (REC: 441/2012) (Appendix C). 
 
3.3.6.  Study participants and demographics 
 
All the runners who registered for the 56km or the 21km races in the 2013 and/or the 2014 Old 
Mutual Two Oceans Marathon in Cape Town, South Africa were considered as possible study 
participants. In this study, 53 976 runners were registered for the 2 races in 2013/14, of which 242 
were seen in the medical facility for a PRIMA consultation. Of these 242 runners (PRIMA 
group), 172 had symptoms suggesting acute illness and comprised the PRIMA-I study cohort 
(n=172). Those runners with diagnoses of a non-infective aetiology comprised the PRIMA-N/I 
group (n=70). The control group of runners for this study comprised the remaining runners who 
did not present to the PRIMA facility at registration (CON=53 734).   
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The demographic data for the runners in all the study groups by gender, and by race type (ultra- 
and half-marathon) are depicted in Tables 3.1a, Table 3.1b, and Table 3.1c. 
 
Table 3.1a.  Demographic data by gender of the runners in the study groups 
 
 CON group  PRIMA group PRIMA-I group PRIMA-N/I group 
N % N % N % N % 
Male 31 489 58.5 158 65.3 100 58.2 58 82.9 
Female 22 315 41.5 84 34.7 72 41.8 12 17.1 
Total 53 734 100 242 100 172 100 70 100 
 
In this study, the PRIMA-I group forms the main cohort and outcome variables will be compared 
between this group and the CON group. There was a similar gender distribution in the PRIMA-I 
group compared with the CON group. 
 
Of the 21 343 runners in the CON group registered for the ultra-marathon, 15 508 (72.7%) were 
male, and 5 835 (27.3%) were female. In the PRIMA-I cohort of 66 Ultra-marathon runners, 52 
(78.8%) were male and 14 were female (21.2%) (Table 3.1b.). Therefore, the proportions of 
runners in the PRIMA-I and CON groups registered for the ultra-marathon were similar. 
 
Table 3.1b.  Demographic data by gender of the ultra-marathon runners in the PRIMA 
and PRIMA-I study groups 
 
 CON group  PRIMA group PRIMA-I group 
N % N % N % 
Male 15 508 72.7 80 77.7 52 78.8 
Female 5 835 27.3 23 22.3 14 21.2 
Total 21 343 100 103 100 66 100 
 
Of the 32 391 runners in the CON group registered for the half-marathon, 15 932 (49.2%) were 
male, and 16 459 (50.8%) were female. In the PRIMA-I cohort of 106 half-marathon runners, 48 
(45.3%) were male and 58 (54.7%) were female (Table 3.1c.). Therefore, the proportions of 









Table 3.1c.  Demographic data by gender of the half-marathon runners in the PRIMA 
and PRIMA-I study groups 
 
 CON group  PRIMA group PRIMA-I group 
N % N % N % 
Male 15 932 49.2 69 49.6 48 45.3 
Female 16 459 50.8 70 50.4 58 54.7 
Total 32 391 100 139 100 106 100 
 
3.3.7.  Main measures of outcome 
 
There were six measures of outcome in this study.  
 
3.3.7.1.  Prevalence of the clinical diagnosis of runners with non-infective acute illness 
(PRIMA-N/I group) 
 
The point prevalence rate (% runners) of final diagnosis in the PRIMA-N/I cohort will be 
reported. 
 
3.3.7.2.  Prevalence of reported symptoms and clinical diagnosis of runners with acute infective 
illness 
 
The point prevalence rate (% runners) of symptoms, and the final diagnosis of acute infection in 
the PRIMA-I cohort will be reported. In addition, the prevalence of runners (%) in the PRIMA-I 
group who failed the ‘neck check’ will be reported. 
 
3.3.7.3.  Advice given to runners with acute infective illness 
 
The advice given to runners will be reported as % runners with a) advice not to run (ANR), b) 










3.3.7.4.  The incidence of not-starting the race (per 1000 runners) (‘Did not start’ rate: DNS  
rate) 
 
All runners were tracked during race day using an electronic chip that was attached to one of the 
shoes of the runner. All runners crossed mats at the starting line, along the route and at the finish 
line where the data in the chip was identified and recorded. A runner was categorised as ‘not-
starting’ if: 
 A start time was not captured from the ‘Champion-chips’ on the start-line mats. 
 A split time was not captured from the ‘Champion-chips’ on the course mats. 
 A finishing time was not captured from the ‘Champion-chips’ at the finish. 
 
3.3.7.5.  The incidence of not-finishing the race (per 1000 runners)(‘Did not finish’ rate: DNF 
rate) 
 
All runners were tracked during race day. A runner was categorised as ‘not-finishing’ if: 
 A runner started, but no finishing time was not captured from the ‘Champion-chips’ at the 
finish line. 
 A runner started but made use of the medical facilities on the course and did not finish the 
race. 
 
3.3.7.6.  The incidence of medical complications during or immediately after the race (per 1000 
runners) (‘Medical complications’ rate: MC rate) 
 
All runners were tracked during race day. A runner was categorised as ‘medical complications’ if: 
 A runner started but was admitted to the medical facility at the finish. 
 A runner started but made use of the medical facilities on the course and did not finish the 
race. 
The procedure for data capture of all medical complications in runners of the Two Oceans race 
has been described (84). 
 
All the outcome measures were analysed in the CON group, the PRIMA group and the PRIMA 




3.3.8.  Statistical analysis of data 
All data were entered into an Excel spreadsheet (Microsoft 2010) and analysed using the SAS 
(V9.3) statistical package (SAS Institute Inc, Cary, North Carolina, USA). Most of the data were 
analysed in two-way tables, using two-tailed Chi-square tests with Yates’ correction factor to 
calculate p-values. In some cases, numbers were too small with <5 data in a field; a Fisher’s exact 
test was then used to calculate probability values of p. P-values of <0.05 are considered 
statistically significant.  
3.4.  Results 
3.4.1.  Prevalence of the clinical diagnosis of runners with non-infective 
acute illness (PRIMA-N/I group) 
The PRIMA N/I cohort consisted of 70 runners, and the prevalence of the final diagnoses of non-
infective aetiology in this group is depicted in Table 3.2. 
Table 3.2. Final diagnoses in the PRIMA-N/I cohort (n=70) 
Diagnosis Number % 
Total 70 100 
Cardiac Arrhythmias 3 4.3 
Hypertension 9 12.9 
MSK 23 32.9 
LRTS 9 12.9 
Other 26 37.1 
Most runners in this group presented with ‘other’ conditions (37.1%). Amongst others, these 
included pregnant runners with concerns, and runners with non-specific medical concerns. The 
most common specific group was musculo-skeletal conditions (32.9%), followed by hypertension 
(12.9%) and non-infective lower respiratory tract conditions (12.9%).   
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3.4.2.  Prevalence of symptoms and clinical diagnosis of runners with 
acute infective illness and the neck check results (PRIMA-I 
group) 
 
3.4.2.1. Prevalence of symptoms in the PRIMA-I group 
 
The PRIMA-I group comprised 172 runners (0.32% of all race registrants) and the prevalence of 
symptoms reported by athletes in this group is depicted in Table 3.3. 
 
Table 3.3.  The prevalence (% in runners) of all reported symptoms in PRIMA-I cohort 
 
Symptom Number % 
Sinus congestion 69 40.1 
Sore throat 65 37.8 
Runny nose 44 25.6 
Cough - non-productive 33 19.2 
Cough - productive 33 19.2 
Fever 23 13.4 
Fatigue 22 12.8 
Other 14 8.1 
General body aches 13 7.6 
Headaches 13 7.6 
Tight chest 11 6.4 
Myalgia 10 5.8 
Shortness of breath 9 5.2 
Earache 8 4.7 
Abdominal cramps 7 4.1 
Chest pain 5 2.9 
Diarrhoea 4 2.3 
Nausea 4 2.3 
Dysuria 1 0.6 
Arthralgia 1 0.6 
Abdominal pain 1 0.6 
Haematuria 1 0.6 
 
The most common symptoms (suffered by >10% of runners) were sinus congestion (40.1%), 
followed by cough (38.4%, but divided between productive and non-productive types evenly), 
sore throat (37.8%), runny nose (25.6%), fever (13.4%) and fatigue (12.8%). Runners could 
report more than 1 symptom, and some reported up to 8 symptoms.   
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3.4.2.2. The final diagnoses in the PRIMA-I group 
 
The final diagnosis based on clinical assessment (either medical history only (MHO) or medical 
history and physical examination (MH+PE)) of runners in the PRIMA-I group is depicted in 
Table 3.4.  
 










All   11 161 172 100  
Localised 
Illness 
URTI Rhinitis – (n-i)  1 27 28 16.3 16.3 
Rhinitis– (i)   2 2 1.2 17.5 
Pharyngitis  2 28 30 17.4 34.9 
Laryngitis   3 3 1.7 36.6 
Sinusitis  6 30 36 20.9 57.5 
Other localised infection  2 2 1.2 58.7 
Systemic illness Generalised URTI 1 38 39 22. 7 81.4 
Syst. infective illness   4 4 2.3 83.7 
Possible myocarditis  1 1 0.6 84.3 
LRTI  18 18 10.5 94.8 
Infective gastro 1 8 9 5.2 100 
 
Of the 172 runners in the PRIMA-I cohort, 99 (57.5 %) had a diagnosis of a localised URTI, and 
2 had a localised other infection. Of the localised URTI, the most common diagnosis was sinusitis 
(20.9%), followed by pharyngitis (17.4%) and non-infective rhinitis (16.3%).  71 (41.3%) runners 
had an illness of a systemic nature. The most common diagnosis was URTI with generalised 
symptoms (22.7%), which was the single most common diagnosis in the entire group. The next 
most common diagnosis was LRTI (10.5%).  
 
3.4.2.3. The neck check status of runners in the PRIMA-I group 
 
In the PRIMA-I group, 101 runners passed the neck check (58.7%), whilst 71 failed the neck 
check (41.3%). The proportions differed on the different days that runners were evaluated before 
the race (Table 3.5.).  The percentages refer to the percentage of the whole PRIMA-I group. 
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As the delay before the race diminished, increasing proportions of runners were evaluated in the 
PRIMA facility.  Almost half (49.4%) of runners were evaluated the day before the race, during 
which the largest proportion of neck check failures (46.5%) were also evaluated.    
 
Table 3.5.  The neck check status of runners in the PRIMA-I cohort (all days, and in 
the 3 days before to the last day just before the race) (n=172) 
Day  Pass  Fail Total N  p-valuea 
 N % N % N %  
Total 101 58.7 71 41.3 172 100 0.0277 
Race -3: 14 8.1 16 9.3 30 17.4 0.2092 
Race -2: 35 20.4 22 12.8 57 33.1 0.386 
Race -1: 52 30.2 33 19.2 85 49.4 0.0205 
Race -3 refers to 3 days before the race, and Race -1 refers to the day before the race 




3.4.3.  Advice given to runners with acute infective illness 
 
The advice given to runners was as follows: a) advice not to run (ANR), b) advice to monitor 
symptoms and information given (Info+MS), and c) information only given (Info only). An 
outcome of ‘Other’ was assigned to runners who were given prescriptions for medication or non-
urgently referred to other health professionals, but where the advice in the record was not clear 
with respect to safety of participation.   
 
In the PRIMA-I group, 11 runners were given advice after a medical history only (MHO): 3 were 
given information only, whilst 8 were also advised to monitor symptoms. The remaining 161 
runners in the PRIMA-I group were assessed by a medical history as well as physical 
examination (MH+PE). The advice given to these athletes is depicted in Table 3.6 with reference 
to the day they were seen.   
 
Table 3.6.  Advice given to runners after MH+PE (n=161) 
 
Day seen ANR Educational information Other Total 
  Info+MS  Info only   
Total 23 82 50 6 161a 
Race-3 3 10 12 3 28 
Race-2 3 41 11 1 56 
Race-1 17 31 27 2 77 
a p=0.0001: calculated for advice given after physical examination. 
ANR: Advised not to race  
 
Overall in the 172 runners of the PRIMA-I group, 143 (83.1%) were given educational 
information. Of these 143 runners, 90 (62.9%) were advised to monitor symptoms, while 53 
(37.1%) received information only.  23 runners were advised not to run, all after a physical 
examination. Further analysis of these 23 runners revealed that all had a systemic illness with 
‘below-the-neck’ features. 12 had a LRTI, 6 a generalised URTI, 4 a systemic infective illness 
and 1 had suspected myo-pericarditis. 
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3.4.4. The incidence of not-starting the race (per 1000 runners)  
(‘Did not start’ rate: DNS rate) 
 
3.4.4.1.  Overall DNS rate 
 
Of all the 53 976 runners who registered for the race in 2013 and 2014, 10 383 (192 per 1000 
runners) did not start the race. The incidence (per 1000 runners) of not-starting the race (DNS 
rate) in all the groups is depicted in Table 3.7. In the CON group of 53 734 runners who did not 
attend the PRIMA facility, there were 10 329 non-starters (DNS rate = 192). Within the PRIMA 
group of 242 runners, 54 runners did not start (DNS rate = 223). There were 41 non-starters in the 
172 runners in the PRIMA-I group (DNS rate = 238).  
 
Table 3.7.  The overall incidence (per 1000 runners) of not-starting the race (DNS rate) 
 
 Starters Non-starters DNS rate 
(per 1000) 
p-value 
N % N % 
CON (n=53 734) 43 405 80.8  10 329 19.2  192  
PRIMA (n=242) 188  77.7 54 22.3 223 0.2561 a 
 PRIMA-I n=172) 131 76.2 41 23.8  238 0.1510 a 
PRIMA-N/I (n=70) 57  81.4  13  18.6 186  0.4704 b 
a Compared to CON 
b Compared to PRIMA-I 
 
There was no significant difference in the DNS rate between the CON groups and any of the 
PRIMA groups.  
 
3.4.4.2.  The DNS rate in the PRIMA-I group based on the method of clinical assessment 
 
The DNS rate in the PRIMA-I group, based on the method of clinical assessment, is depicted in 
Table 3.8. In the 172 runners in the PRIMA-I group, 11 were advised on the basis of medical 
history only (MHO). Only 1 runner did not start, indicating a DNS rate of 91. Of the 161 runners 
who were assessed by medical history and physical examination (MH+PE), there were 40 non-
starters (DNS rate = 249).  
 
There was no significant difference in the DNS rate between the groups. The number of non-
starters in the MHO group was too small for statistical analysis (n=1).  
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Table 3.8.  The DNS rate in the PRIMA-I group based on the method of clinical 
assessment (MHO and MH+PE)  
 
 Starters Non-starters p-value 
N % N DNS 
rate 
 
CON (n=53 734) 43 405 80.8  10 329 192   
PRIMA-I  (n=172) 131 76.2 41 238  0.1510 a 
 MHO (n=11) 10 90.9 1 91  
MH+PE (n=161) 121 75.2 40 249 0.0878 a 
a Compared to CON 
DNS rate: Runners who did not start (per 1000 runners) 
 
3.4.4.3.  The DNS rate in the PRIMA-I group based on advice given 
 
The DNS rates in the PRIMA-I group based on advice given is depicted in Table 3.9.  
 
Table 3.9.  The DNS rate in the PRIMA-I group based on advice given   
 
 Starters DNS p-value 
N % N DNS 
rate 
 
CON (n=53 734) 43 405 80.8  10 329 192   
PRIMA–I (n=172) 131 76.2 41 238  0.1510 a 
 Info (n=143) 116 81.1 27 189 0.9176 a 
 Info only (n=53) 47 88.7 6 113 0.1988 a 
Info+MS (n=90) 69 76.7 21 233 0.3926 a 
ANR (n=23) 10 43.5 13 565 < 0.0001 a 
Other (n=6) 5 83.3 1 167 - 
a Compared to CON 
DNS rate: Runners who did not start (per 1000 runners) 
 
There was no significant difference in the DNS rate between the main or sub-groups, compared to 
the CON group. However, in the group of 23 runners who were advised not to run (ANR), there 
were 13 non-starters (DNS rate = 565) and this is a significant increase in the DNS rate compared 
to the CON group. This indicates that 43.5% (the 10 runners who started) of this ANR subgroup 
were non-adherent to advice, while 56.5% were adherent.   
 
3.4.4.4. The DNS rate in the PRIMA-I group based on the neck check 
 
The DNS rates in the PRIMA-I group based on the neck check is depicted in Table 3.10. Of the  
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172 runners in the PRIMA-I group, 101 (58.7%) passed and 71 (41.3%) failed. The DNS rate was 
analysed overall, as well as depending on the day of PRIMA assessment. The DNS rate was 
compared between those runners seen within the day before the race (Race ≤ -1), and those seen 
more than a day before the race (Race >-1).   
Table 3.10.  The DNS rate in the PRIMA-I group based on the neck check 
Starters DNS p-value
N % N DNS 
rate 
CON (n=53 734) 43 405 80.8  10 329 192  
Pass (n=101) 82 81.2 19 188 0.9167 a 
Race >-1 (n=49) 44 89.8 5 102 0.1555 a 
Race ≤ -1 (n=52) 38  73.1 14 269 0.2178 a 
Fail (n=71) 49 69.0 22 310 0.0182 a 
Race >-1(n=38) 31 81.6 7 184 0.9003 a 
Race ≤ -1 (n=33) 18  54.5 15 455 < 0.0001 a 
a Compared to CON 
DNS rate: Runners who did not start (per 1000 runners) 
Race >-1: seen more than 1 day before the race 
Race ≤ -1: seen within 24 hours before the race 
In runners who passed the neck check, there was no significant difference in the DNS rate 
compared to the CON group. However, in the 71 runners who failed the neck check, 22 did not 
start (DNS rate = 310) and this was significantly higher than the DNS rate in the CON group 
(p=0.0182). Furthermore, when analysing the DNS rate according to the day of assessment, a 
failed neck check on the day before the race resulted in a significantly higher DNS rate (455), 
compared to the CON group (p<0.0001).   
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3.4.5. The incidence of not-finishing the race (per 1000 runners) 
(‘Did not finish’ rate: DNF rate) 
 
3.4.5.1.  Overall DNF rate 
 
In 2013 and 2014, 43 593 runners started the race; 42 920 (98.5%) finished the race while 673 
runners did not finish (DNF rate = 15.4). The overall DNF rates are depicted in Table 3.11. In the 
CON group 43 405 started the race and 666 did not finish (DNF rate = 15.3), while 188 runners in 
the PRIMA group, started and 7 did not finish (DNF rate = 37.0)  
 
Table 3.11.  The DNF rate in all groups of starters 
 
 Finishers DNF p-value 
N % N DNF rate  
Control (n=43 405) 42 739 98.5 666 15.3  
PRIMA (n=188) 181 96.3  7  37.2 0.0329 a 
 PRIMA-I (n=131) 127 97.0  4  30.5  - 
 PRIMA-N/I (n=57) 54 94.7 3 52.6 - 
a Compared to CON 
DNF rate: Runners who did not finish the race (per 1000 runners) 
 
In the PRIMA group, 181 (96.3%) runners finished the race. However, the DNF rate (37) in the 
PRIMA group was significantly higher compared to the CON group (15.3) (p=0.0329). Although 
the DNF rates in both the PRIMA-I and PRIMA-N/I groups appear higher than that of the CON, 
statistical analysis was not performed because of the small sample sizes. Of the 7 runners who did 
not finish in the PRIMA group, all 7 were ultra-marathon runners, and 4 had symptoms of acute 
illness. 
 
3.4.5.2.  The DNF rate in the PRIMA-I group based on the method of clinical assessment 
 
The DNF rates in the PRIMA-I group based on the method of clinical assessment are as follows. 
All 10 starters who had been assessed by MHO only, finished the race. Of the 121 starters who 
had been assessed by MH+PE, 4 did not finish (DNF rate = 33). Although there was an apparent 
higher DNF rate in the MH+PE group compared to the CON group, statistical analysis was not 
performed because of the small sample sizes. 
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3.4.5.3. The DNF rate in the PRIMA-I group based on advice given 
 
The DNF rates in the PRIMA-I group based on advice given are as follows. All the runners who 
had been advised after the medical history only (n=10) finished the race. In the PRIMA-I group, 4 
runners did not finish the race. Of these, 2 runners had been given information only, while 1 was 
also advised to monitor symptoms. The fourth had been advised not to run. Although the DNF 
rate is higher in the group of runners who had been advised after MH+PE (DNF rate = 33.1), 
compared to that of the CON group (DNF rate = 15.3), it was not statistically significant 
(p=0.0671).  
 
3.4.5.4.  The DNF rate in the PRIMA-I group based on the neck check 
 
The DNF rates in the PRIMA-I group based on the neck check are as follows. In the PRIMA-I 
group 82 runners passed the neck check and started, only 1 did not finish (DNF rate = 12.2), but 
this was not statistically analysed because of the small sample size. In the PRIMA-I group 49 
runners who started the race despite failing the neck check, 3 did not finish (DNF rate = 61.2). 
Two of the 3 runners were assessed on the day before the race. We note that the DNF rate in the 
runners who failed their neck check (61.2) appears to be higher than that of the CON, but 
statistical analysis could not be performed because of the small sample size. 
 
3.4.6. The incidence of medical complications during or immediately   
   after the race (per 1000 runners)  
 (‘Medical complications’ rate: MC rate) 
 
Of the 43 618 runners who started, 297 runners developed medical complications during or after 
the race, indicating a MC rate of 6.8 / 1000 starters. The MC rate in the CON group was 6.77 per 
1000 starters, and there were no medical complications in the PRIMA-I group of runners who 






The main findings of this study relate to 1) clinical epidemiological data regarding acute illness in 
a cohort of runners with symptoms of acute illness in the 3 days before an endurance running 
event who were assessed at a medical facility, and 2) follow-up race participation data (not 
starting, not finishing and development of medical complications) in this cohort of runners.   
 
3.5.1. Clinical epidemiology of acute illness in the pre-competition  
period  
 
The main findings of this component of the study were that 1) more than 25% of runners who 
presented with symptoms of acute illness, had URT symptoms of sinus congestion, sore throat 
and runny nose, 2) lower RTS and systemic symptoms were common, with 38.4% of runners 
complaining of a cough (either productive or non-productive), 13.4% reporting fever and 12.8% 
complaining of fatigue, 3) in 93.6% of cases, a physical examination was conducted, in addition 
to a medical history, to make the diagnosis, 4) localised URTI comprised the majority of the 
diagnoses, (about 56% of ill runners), and 5) the most common individual diagnosis was URTI 
with generalised symptoms (22.7%).   
 
We are not aware of any study where similar data have been reported. Therefore, there are no 
data for comparison but available evidence from studies conducted during events and tournament 
also report that URTI is the most common cause for acute illness in athletes. These data are based 
on tournament settings and self-reported symptoms only settings (15, 20-25). However, it is of 
interest that 9 of the 70 runners (12.9%) in the PRIMA-N/I cohort had RTS of non-infective 
origin. Some of these were diagnosed as allergic and others as wheezing after respiratory 
infection (WARI) or a post-infective cough. These data supports previous suggestions that a 
significant proportion of RTS, presumed to be infective in nature, may in fact have a different 
underlying aetiology (12, 13, 16, 18, 19).  
 
3.5.2.  Race participation data 
 
The main findings related to participation data are that 1) 43.5% of runners who had been advised 
not to run, were non-adherent to this advice and started the race, 2) runners who passed the neck 
check were able to start and finish the race in a similar proportion to runners who did not present 
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with an acute illness (CON group), 3) runners who failed the neck check had a significantly 
higher rate of not starting compared to runners who did not present with an acute illness (CON 
group), 4) 54.5% of runners started despite a failed neck check, 5) runners who were assessed at 
the PRIMA facility had a higher incidence of not finishing the race, 6) there is some evidence to 
suggest that runners who failed the neck check had a greater risk of not finishing the race, but this 
finding was limited by small numbers, and 7) no runners in the PRIMA-I group, who started the 
race, reported medical complications at the race medical facilities.   
 
The incidence of not-starting the race was used to determine adherence to advice given to the 
runners. Most runners appear to have adhered to advice given and there was a significantly 
greater DNS rate (per 1000 runners) in these runners compared to the CON group (565 vs. 192).  
However, it should also be noted that almost 45% of runners were non-adherent to this advice. An 
aspect of the educational information discussed with runners was the importance of monitoring 
symptoms. Advice was given with the intention of assisting runners make an informed decision 
about their fitness to compete. There may have been valid reasons for runners not to adhere to the 
advice given. There was a delay of up to 3 days before the race for some runners, and it is 
possible that their condition may have improved sufficiently to consider starting on race day. This 
delay may be responsible for some of those runners who started the race despite a failed ‘neck 
check’ or advice not to race. However, it should be noted that 73.9% (n=17) of the runners who 
were advised not to race, were examined within 24 hours of the race start, making this possible 
reason unlikely. Furthermore, running ‘folk-lore’ suggests that runners are notorious for ignoring 
medical advice. In fact, this may have had an impact on preventing runners from seeking help at 
the PRIMA facility, as several runners indicated that they did not want to be told they should not 
be running. Of interest was that when some of the ultra-marathon runners were advised against 
participating, they frequently expressed a wish to participate in the half-marathon instead, 
perceiving it as less ‘risky’. This is in accordance with data describing drop-outs in the Aberdeen 
marathon in 1984, where a third of the ‘drop-out’ respondents indicated they would have entered 
a half-marathon if given the option (70).   
 
It is interesting to note that the DNS rate in the entire race population was 192 per 1000.  This is a 
much lower rate than has previously been recorded in the literature. There are not many data, but 
information from three studies indicate that pre-race ‘drop-out rates’ in marathon races vary 
between 30-55%, mainly due to injury, illness and motivational reasons (70-72). Entries to the 
Two Oceans Marathon races are highly sought after, especially the half-marathon, which is 
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usually oversubscribed (85) and this may explain the lower ‘drop-out’ rate in this race compared 
with the data reported from other races.   
In this study, 56.5% runners who were advised not to run apparently took this advice and did not 
start. We acknowledge that their illness may not have been the only reason for not starting. In 
terms of general advice given to runners, there was a DNS rate of 56 in those runners who were 
given information only, 233 in those who were advised to monitor symptoms and the afore-
mentioned 565 in those advised not to run. This difference in the DNS rate may indicate the 
severity of their illness and that those runners who were advised not to run were more ill than 
those advised to monitor symptoms, or those who received information only. We are not aware of 
any data in the published literature that explore the concept of adherence to advice against 
participating, when athletes have evidence of acute illness.    
The neck check is a clinical tool that SEM physicians use to advise athletes regarding safety to 
participate if they suffer from a recent or a current acute illness. To our knowledge, there are no 
clinical studies that explored the application of the neck check in a population of athletes with 
acute illness in the pre-competition period. Therefore, we cannot compare our results to any 
published data. In our study, runners with localised or minimal pre-race illness who passed the 
neck check i.e. had ‘above-the-neck’ symptoms, had the same chance of starting the race as 
runners in our control group. Furthermore, of those runners who started after passing their neck 
check, 98.8% finished the race and did not have any medical complications. Therefore, advice to 
allow participation in runners with ‘above-the-neck’ symptoms appears to be safe and have no 
impact on the ability to complete the race. These data are, to our knowledge, the first clinical data 
from a prospective study to indicate that the ‘neck check’ is a useful and valid clinical tool to 
advise athletes with acute illness on RTP. However, we do encourage further research in this area, 
particularly with more specific diagnoses and larger sample sizes, and more accurate measures of 
performance (e.g. split and finishing times compared to previous or personal best running times). 
We also note that 90% of the starters, who had been advised not to run, finished the race without 
medical complications. The diagnoses in this group of runners (advised not to run) were all 
systemic in nature. Our study sample size is too small to imply that running with such conditions 
is safe, but it does indicate that further clinical studies with larger numbers are important, 
particularly as there are documented risks of exercising whilst suffering from a systemic infection 
(Chapter 2).   
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A failed neck check was associated with a significantly higher incidence of non-starters; this 
increase was even more significant when runners were seen within 24 hours of the race start. As 
the time between examination and race decreased, there was an increasing proportion of non-
starters in both groups – passed and failed neck check. The highest proportion of neck check 
failures was seen on Race Day -1 (i.e. the day before the race), although this coincided with 
almost half (49.4%) of the PRIMA-I cohort being seen on that day. In these runners, there was a 
minimal time delay between advice and the race, allowing little time for improvement of clinical 
condition. Despite this, more than 50% (54.5%) failed to adhere to the advice that would have 
cautioned against starting with ‘below-the-neck’ symptoms.   
 
The DNF rate in the runners who failed a neck check (61 per 1000) appears to be higher than the 
CON group (16), but this finding should be interpreted with caution due to the small numbers of 
participants in these groups. Further studies with larger sample sizes are needed.   
 
There were no medical complications recorded for the PRIMA-I cohort, compared to the overall 
race incidence of medical complications of 6.81 per 1000 starters. The overall incidence of 
medical complications for this race has previously been reported as 8.27 per 1000 over a 4 year 
period (84). In evaluating the role of a pre-race registration medical facility it is perhaps expected 
that the ‘acutely ill runners’ would have a higher incidence of medical complications. However, 
this was not the case in this study. We suggest that the advice provided to all athletes during 
PRIMA consultations may have reduced the risk of short-term medical complications in runners 
with pre-race symptoms of acute illness. However, this requires further study with a larger sample 
size.  
 
In the PRIMA-N/I (non-infection) cohort, the PRIMA facility played a role in the prevention of 
potential medical complications. In this group, 2 runners were referred for suspected DVTs, while 
a third runner was found to have runs of SVT of 240 beats / min in the days prior to the race. A 
fourth runner had significant hypertension with a BP of 194/114 mmHg. These runners were 
advised against running due to the risk of cardiac or pulmonary complications and were referred 






3.5.3.  Strengths and limitations of the study 
 
This study has a number of strengths. Firstly, as far as we are aware, this study is the first to 
document the clinical epidemiology of illness in athletes in the 3 days before an event, and then 
document follow-up race participation data (not starting, not finishing and development of 
medical complications) in this cohort of runners in the form of a prospective study. Secondly, an 
accurate clinical diagnosis was made by qualified medical staff in the cases of ill runners. This is 
in contrast to previous studies that relied on self-reported data only. Thirdly, we were able to 
compare our data to a large control group of runners.  
 
There are however also some limitations of this study. Firstly, the cohort of runners in the 
PRIMA group was of a self-selected nature. Therefore the prevalence of acute illness in the entire 
race population is not known. It is likely that some runners in the control group also suffered from 
symptoms of acute illness but did not report to the PRIMA facility. This has implications for the 
DNS, DNF and MC rates, which may be affected by runners in the CON group that also suffered 
from acute illness at the time of the race. Therefore, if anything, the DNS, DNF and MC rates of 
runners with no illness are lower than that reported for the CON group in this study. Secondly, we 
did not identify the reasons for not starting or finishing a race in runners. Therefore, we cannot 
assume that not-starting or not-finishing was as a result of acute illness or advice given. This 
should be determined in future studies of this nature. Finally, we acknowledge that the sample 
sizes were very small in some of our sub-groups, and we could therefore not perform adequate 
statistical analyses of these sub-groups. Future studies with larger participant numbers will 
address these limitations. 
 
3.5.4. Summary and conclusion  
 
In conclusion, this study is the first to investigate a pre-race population of runners with acute 
illness that were diagnosed after a clinical assessment. In this cohort of 172 ultra- and half 
marathon runners, the majority of acute illness was localised to the upper respiratory tract, but a 
significant number of runners had an URTI with generalised symptoms, as well as LRTI. These 
runners were given advice on participation guidelines, based on the neck check. More than half of 
the runners, who were advised not to run, appear to have taken heed of this advice. Of concern 
were the 43.5% who were non-adherent to advice. The vast majority of race starters finished 
safely, supporting the first tenet of the neck check i.e. exercising with ‘above-the-neck’ (localised 
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URT symptoms) is safe. The lack of medical complications in the small number of those runners 
who exercised with ‘below-the-neck’ / systemic symptoms, should not be used to imply safety 
and further studies with larger sample sizes are needed. However, this study therefore provides 
the first clinical data to support the application and safety of the neck check as a participation 
guideline in athletes with acute illness in the pre-competition period. However, further studies 
should also investigate the effects of different types of infections as well as the sub-acute health 





Summary and conclusion 
 
4.1.  Summary of main findings  
 
The focus of this dissertation was to gain an understanding of current participation guidelines 
with respect to acute illness in athletes. In Chapter 2, the evidence behind the current guidelines, 
which are based on the neck check, a clinical tool commonly used by SEM physicians, was 
reviewed. This review indicated that there have been no clinical studies that investigated the use 
of the neck check as a participation guideline in such athletes. Furthermore, there is no indication 
in the literature as to whether athletes adhere to the medical advice they are given. With these 
questions in mind, the original research component was undertaken.  
 
From an epidemiological perspective, the review indicated that the upper respiratory tract is the 
most common source of symptoms of illness in athletes. However, the literature in this regard is 
based on self-reported symptomatology as opposed to confirmation of the diagnosis following 
clinical examination or special investigations. There is good evidence that not all URTS are 
infective in nature, and they may be related to allergy or inflammation of unknown aetiology, 
induced by physiological stress. The value of physical examination in addition to a medical 
history only, was confirmed. The review furthermore showed that there is a ‘Participation risk’, 
pertaining to acute illness in athletes. There are potential medical complications of exercising 
whilst ill and these include the potential risks of sudden cardiac death (SCD) when exercising 
with sub-clinical myocarditis, splenic rupture in patients with infectious mononucleosis (IM), 
electrolyte disturbance with gastroenteritis, reductions in pulmonary function with lower 
respiratory tract infection (LRTI) and influenza, as well as acute renal failure and exertional 
heatstroke. There are also few clinical data and little scientific reports on the effects of acute 
illness on impaired exercise performance and non-participation as a result of acute illness. The 
history and the evidence base for the validity of the neck check, in terms of safety of exercising 
with localised URTS, as well as potential risks of exercising with lower respiratory or systemic 
illness were reviewed. It was concluded that there are very few clinical and research data 
supporting the use of the ‘neck check’ to advise athletes on return to play (RTP) following an 
acute illness.   
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Therefore, the research study in this dissertation is, according to our knowledge, the first study 
that examined the epidemiology of illness in a pre-race cohort of runners, and then followed these 
runners until after the race to assess adherence to advice, race starting and finishing as well as 
medical complications. In this cohort of 172 runners, localised URTI constituted the majority of 
clinical diagnoses, of which sinusitis, pharyngitis and non-infective rhinitis were the most 
common diagnoses. These findings support the evidence suggesting that URTS are the most 
common cause of infection in athletes. This is important as we know that there is a significant 
overlap between the symptoms of these conditions, especially sinusitis and rhinitis, and 
symptoms of allergy. However, the single most common diagnosis in our study was that of an 
URTI with generalised symptoms. A novel finding in our study is that our data support the short-
term safety of exercising with symptoms of localised URTI i.e. a ‘passed’ neck check, as 96.95% 
of the starters in the study cohort finished without requiring medical assistance during or after the 
race.  
 
However, we do report that a failed neck check increased the incidence of not starting the race, as 
well as increasing the incidence of not finishing in those who started. Further studies with larger 
sample sizes are required to investigate the race participation outcomes and medical complication 
rate in those runners with a failed neck check, or suffering from ‘below-the-neck’ or systemic 
illness. Although the results of our study suggest that it is safe to use the ‘neck check’, further 
studies with larger sample sizes are required to confirm this finding. We do suggest that pre-race 
medical facilities that assist athletes with symptoms of acute illness have the potential to reduce 
the risk of medical complications in a large endurance event, and this also needs further 
exploration in studies with larger sample sizes. Finally we do note, with some concern, that there 
was a high level of non-adherence to advice given against participation (43.5%) in a pre-race 
registration medical facility. The reasons for this high level of non-adherence also need to be 
explored in future studies.  
 
4.2.  Clinical implications of findings 
 
The current participation guidelines for athletes with acute illness were summarised in the 
concluding section of Chapter 2. In the evaluation of an athlete with symptoms suggesting acute 
illness in the pre-competition period, the following are additional suggestions to these guidelines 
for the SEM physician, based on the findings of this dissertation: 
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1. A pre-race registration medical facility should be considered in all large endurance events
with a view to reducing potential medical complications.
2. The medical assessment at such a facility should include both a medical history and
physical examination by a SEM physician.
3. Aetiologies other than infection for upper respiratory tract symptoms should be
considered: the medical history should specifically enquire about allergies.
4. Physical examination is necessary to rule out diagnoses such as streptococcal pharyngitis,
infectious mononucleosis and possible myocarditis. Body temperature, resting heart rate
and respiratory rate should be noted. Special investigations may be helpful, specifically
rapid assays for GABHS, serum inflammatory and cardiac markers, and a resting ECG.
5. The neck check appears to be a safe clinical tool to direct participation advice, especially
in those runners with ‘above-the-neck’ illness.
6. Education of athletes during encounters at such facilities is essential for runners to make
an informed decision about their individual participation risk on the day of the race.
4.3.  Suggestions for further research 
We suggest that further research be conducted in this area, particularly an extension of this study 
with a larger sample size. The following additional areas for research should be considered in a 
larger cohort: 
1. Determining risk factors for infection:
 Training load is described as a risk factor for infection: training history could be
analysed in this cohort. It is anticipated that there may be proportionally more
illness in the ultra-marathon sub-population.
 History of allergy increases the risk of symptoms of URTI – medical history
could be examined.
 Recent or current symptoms of infection and exploring if these are a risk factor
for developing medical complications during or after an endurance event.
 Exploring other risk factors for acute illness including presence of other chronic
diseases in runners, use of medication and supplements, age of runners, and the
possible effects of travelling.
2. Exploring the possible effects of illness on performance by examining finishing and split
times, and also comparing to previous race times or personal best times.
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3. Determining the effect of a failed neck check on exercise performance and potential 
medical complications. 
4. Exploring the safety and effects on performance when exercising with WARI (wheezing 
following respiratory tract infections), which is a known complication that appears to 
affect certain sub-groups of athletes. Such data are lacking. Although some of the runners 
in the PRIMA group were noted to have post-infectious respiratory tract symptoms, there 
were too few numbers for analysis.  
5. Determining if there are differences in race participation and safety with regard to 
specific diagnoses i.e. specific localised URT infection or systemic illnesses.  
6. Conducting follow-up studies to ascertain the following: 
 Reasons for not-starting the race. 
 Reasons for non-adherence to advice if advised against participation. 
 Medical complications, which may have arisen in the days or weeks following 
the race. 
7. Exploring, through laboratory-based research, the development of a simple novel 
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Appendix B: Electronic questionnaire completed in the Health Village for  
 PRIMA Consultation 
 
1. Date [free text, compulsory] 
 
 
2. Runner Identification  
 
Surname  [free text, compulsory] 
First name  [free text, compulsory] 
Sex   [drop down box, single select, compulsory] 
Male  
Female  
Age  [free text, compulsory] 
Cell number [free text]  
Race number  [free text, compulsory]  
Race  [drop down box, single select, compulsory] 
 21 km 
 56 km 
 Short trail run 
Long trail run 
Fun run  
 Other:  [free text]  
 
3.  Runner triaged by [free text compulsory] 
 






Cough – non-productive 












Nausea and vomiting 
Palpitations 
Runny nose 





Other:   [free text box] 
 
 
5. What are the secondary presenting symptoms? (You may select more than one.)  






Cough – non-productive 












Nausea and vomiting 
Palpitations 
Runny nose 




Other:   [free text box] 
 
 












7. [If NO was clicked in question 6a or 6b]  
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What advice was given? (you may select more than one)  [drop down box, 
multiple select, compulsory] 
 
Advised not to race 
Advised to monitor symptoms and decide on race day 
Educational information given and discussed – Acute infections 
Educational information given and discussed – Gastroenteritis 
Educational information given and discussed – Respiratory tract infections 
Medication prescribed:  [free text box] 
Referral to Dr/hospital – non-urgent 
Referral to Dr/hospital – urgent 
Other:  [free text] 
 
 
8. [If YES was clicked in question 6a and 6b] 
Physical examination (vital signs) 
 
Resting heart rate  [free text box] 
Resting systolic pressure [free text box] 
Resting diastolic pressure [free text box] 
Tympanic temperature  [free text box] 
 
9. Runner examined by: [free text compulsory] 
 
10. Physical examination (general) (you may select more than one)    
    [drop down box, multiple select, compulsory]  
None 
Pale      
Jaundice     
Cervical lymphadenopathy – right neck  
Cervical lymphadenopathy – left neck  
Peripheral oedema    
 Clammy/sweaty    
Abnormal skin turgor     
Dry mucous membranes  
Other  [free text]  
 
11. Physical examination (ENT)  [drop down box, single select, compulsory] 
 




If abnormal, please indicate findings (you may select more than one): [drop down 
box, multiple select] 
Nasal discharge – clear 
Nasal discharge – purulent 
Nasal discharge – bloody 
Otorrhoea 
Pharyngitis – mild erythema 
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Pharyngitis – with exudate 
Pharyngitis – with other signs 
Post-nasal drip 
Sinus tenderness – maxillary 
Sinus tenderness – frontal 
Sinus tenderness – other 
Tonsillitis 
Tympanic membrane erythema 
Other: [free text] 
 
12. Physical examination (respiratory) [drop down box, single select, compulsory] 
Not indicated 
Normal (no evidence of crepitation, effusion, rhonchi, rub, wheezing etc.) 
Abnormal   
 
If abnormal, please indicate findings (you may select more than one): [drop down 






Other: [free text box] 
 






If abnormal, please indicate findings (you may select more than one): [drop down 
box, multiple select] 
Tender – no peritonitis 
Tender – suspicious of peritonitis 
Other:  [free text] 
 




Abnormal:  [free text] 
 





Abnormal:  [free text] 
 





Abnormal  [free text] 
 
17. Physical examination (other) :  [free text] 
 
 




Angina – unstable 
Arrythmia – ventricular 
Arrhythmia – supraventricular  
Arrythmia – other 
Bronchospasm 
Chest pain – unspecified 
Gastroenteritis – mainly diarrhoea 
Gastroenteritis – mainly vomiting 
Gastrointestinal disease – other 
Laryngitis – localised 
Lower respiratory tract infection 
Myopericarditis (suspected) 
Otitis media 
Pharyngitis – localised 
Rhinitis – localised – infected 
Rhinitis – localised – non-infected 
Sinusitis – localised 
Upper respiratory tract infection – generalised 
UTI (suspected) 
Other: [free text] 
 
 
19. Additional clinical problems/diagnoses? (you may select more than one) [drop down 
box, multiple select] 
 
Angina- stable 
Angina – unstable 
Arrythmia – ventricular 
Arrhythmia – supraventricular  
Arrythmia – other 
Bronchospasm 
Chest pain – unspecified 
Gastroenteritis – mainly diarrhoea 
Gastroenteritis – mainly vomiting 
Gastrointestinal disease – other 
Laryngitis – localised 




Pharyngitis – localised 
Rhinitis – localised – infected 
Rhinitis – localised – non-infected 
Sinusitis – localised 
Upper respiratory tract infection – generalised 
UTI (suspected) 
Other: [free text] 
 
 
20. What advice was given? (you may select more than one)  [drop down box, 
multiple select, compulsory] 
 
Advised not to race 
Advised to monitor symptoms and decide on race day 
Educational information given and discussed – Acute infections 
Educational information given and discussed – Gastroenteritis 
Educational information given and discussed – Respiratory tract infections 
Medication prescribed:  [free text box] 
Referral to Dr/hospital – non-urgent 
Referral to Dr/hospital – urgent 





Appendix C: Three informational leaflets given to athletes at a PRIMA  
  consultation 
 
1.  Guidelines: Running and acute infections 
 
Guidelines 
Running and acute infections 
Runners that are training very hard may be more susceptible to acute (new onset) 
infections. Therefore, at the peak of your preparation for the race you may have 
symptoms of an acute infection. These vary according to the body system that is 
affected but the common general symptoms of an infection are: fever, headache, 
general body aches and pain, and excessive tiredness (malaise). Depending of the body 
part that is affected, other symptoms may also be present.  
If you have symptoms of any acute infection (including bladder infections, skin infections 
etc.), especially in the week before the race, we strongly urge you to seek a medical 
opinion from a qualified medical doctor.  
Taking part in exercise while having an infection can be very detrimental to your health 
and can cause serious complications. Some of the infective agents (viruses or bacteria) 
can, for example, affect the heart muscle (known as myocarditis), resulting in heart 
muscle damage and even sudden cardiac death. There are very strict guidelines to 
assist you in preventing complications during running when you have symptoms of an 
infection.  
Please take note that if you have any of the following symptoms of an infection, it is 
recommended that you do NOT take part in exercise: 
 Fever 
 General muscle pains 
 General joint pains 
 Chest pain 
 Increase in your resting pulse rate 
 Shortness of breath (more than usual) 
 General tiredness (fatigue) that is more than usual 
If you have any of these symptoms, or other symptoms of an infection, we suggest that 
you do NOT train or race, and consult your doctor for further advice and treatment. 
At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and infections. 
Old Mutual Two Oceans Marathon Medical Team 





2. Guidelines: Running and respiratory tract infections 
 
Guidelines 
Running and respiratory tract infections 
(“flu” and “common cold”) 
 
Respiratory tract infections are the most common infections of affecting athletes and are 
caused by viruses (mostly), bacteria or other organisms. However, symptoms of 
respiratory tract infections may also be caused by a non-infectious cause such as an 
allergy. These infections mainly affect the nose, sinuses or throat area and are then 
known as upper respiratory tract infections.  
Symptoms of an upper respiratory tract infection are blocked nose, runny nose, sore 
throat, and painful sinuses. These infections do not usually result in symptoms affecting 
the whole body (fever, muscle pain, joint pain, general tiredness).  
If the infection spreads to the airways and lungs this is known as a lower respiratory tract 
infection. Typical symptoms of a lower respiratory tract infection are cough, chest pain, 
and shortness of breath. Usually, but not always, these infections are associated with 
symptoms affecting the whole body (fever, muscle pain, joint pain, general tiredness). 
 
Running and respiratory tract infections 
Taking part in exercise while having an infection can be very detrimental to your health 
and can cause serious complications. Some of the viruses can affect the heart muscle 
(known as myocarditis), resulting in heart muscle damage and even sudden cardiac 
death. Please remember that other infections, such as measles and chickenpox affect 
the respiratory tract and your whole body. They are contagious and it is recommended 
that you do not exercise when you suffer from these illnesses.  
There are very strict guidelines to assist you in preventing complications during running 
when you have symptoms of a respiratory tract infection.  
Please take note that if you have any of the following symptoms of respiratory tract 
infections, it is recommended that you do NOT take part in exercise: 
 Fever 
 General muscle pains 
 General joint pains 
 Chest pain 
 Increase in your resting pulse rate 
 Shortness of breath (more than usual) 
 General tiredness (fatigue) that is more than usual 
 Severe sore throat 
 Swollen and painful lymph nodes in your neck 
If you have any of these symptoms we suggest that you do NOT train or race, and 
consult your doctor for further advice and treatment. 
In some mild cases where your symptoms are only in the upper respiratory tract (no 
generalized body symptoms) your doctor may allow some form of low-moderate intensity 
exercise.  If you do decide to race, we suggest you see how you feel after 10 minutes or 
so.  If you feel unwell we suggest that you stop running. 
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At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and respiratory tract infections. 
When can you resume running after a respiratory tract infection? 
It is suggested that you can return to running after a respiratory tract infection only when 
all your symptoms have disappeared and you feel well again. If you are not sure, please 
have an evaluation by a qualified medical doctor.  
 
Old Mutual Two Oceans Marathon Medical Team 
Prof Martin Schwellnus, Prof Wayne Derman, Dr Karen Schwabe, Dr Wayne Smith 
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3. Guidelines: Running and gastro-enteritis
Guidelines 
Running and gastro-enteritis (gastro-intestinal 
infections) 
Gastro-enteritis (including gastro-intestinal infections), is very common in athletes, 
particularly when travelling. The causes of gastro-enteritis can be as a result of an 
infection or a toxin (“food poisoning”). The typical symptoms of gastro-enteritis are 
nausea, vomiting, diarrhoea and abdominal cramping (pain).  
Acute gastro-enteritis can have detrimental effects on your ability to run, largely as a 
result of dehydration and electrolyte disturbances. Electrolytes are the salts in your blood 
such as sodium and potassium.  Symptoms affecting your whole body such as fever, 
muscle pain, joint pain, and general tiredness may also occur.  
There are very strict guidelines to assist you in preventing complications during running 
when you have symptoms of gastro-enteritis. Running with gastro-enteritis may 
aggravate the effects of dehydration and electrolyte abnormalities, which can cause 
confusion or other brain disturbances, or trigger abnormal heart rhythms and possibly 
even sudden cardiac death. 
Please take note that if you have any of the following symptoms of gastro-enteritis, it is 
recommended that you do NOT take part in exercise: 
 Fever
 General muscle pains
 General joint pains
 Dehydration (dizziness when standing, decreased urine volume and concentrated
urine, thirst, dry mouth and decreased saliva production)
 On-going nausea and vomiting
 On-going abdominal cramps
 Increase in your resting pulse rate
 General tiredness (fatigue) that is more than usual
If you have any of these symptoms we suggest that you do NOT train or race, and 
consult your doctor for further advice and treatment. 
At the Two Oceans registration (Expo) there will be medical staff to assist you if 
you do have any of these symptoms. The staff will be able to offer advice on 
running and gastro-enteritis. 
Old Mutual Two Oceans Marathon Medical Team 
Prof Martin Schwellnus, Prof Wayne Derman, Dr Karen Schwabe, Dr Wayne Smith 
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